



(51) International Patent Classification:

C12N 5/0783 (2010.01) A61K 39/12 (2006.01)
A61P 35/00 (2006.01) C07K 16/28 (2006.01)
A61K 35/17 (2015.01) A61K 31/551 (2006.01)
A61K 39/245 (2006.01) A61K 31/4184 (2006.01)
A61P 31/22 (2006.01) A61K 31/519 (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/AU2020/051147

(22) International Filing Date:

23 October 2020 (23.10.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2019903995 23 October 2019 (23.10.2019) AU

(71) Applicant: THE COUNCIL OF THE QUEENSLAND
INSTITUTE OF MEDICAL RESEARCH [AU/AU];
300 Herston Road, Herston, Queensland 4006 (AU).


(72) Inventors: KHANNA, Rajiv; 300 Herston Road, Herston,
Queensland 4006 (AU). SINHA, Debottam; 300 Herston
Road, Herston, Queensland 4006 (AU).

(74) Agent: CLARKE, Andrew; James & Wells, GPO 1920,
Brisbane, Brisbane, 4001 (AU).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: ADOPTIVE IMMUNOTHERAPY



(57) Abstract: Disclosed herein is the use of a first population of allogeneic T-cells recognizing a first EBV epitope, and a second allogeneic population recognizing a second EBV epitope in the treatment of EBV-associated disorders. Also disclosed is the use of a population of allogeneic T-cells recognizing an EBV antigen in combination with a further therapeutic agent such as an immunotherapeutic agent, a MAPK, BET or MEK. pathway inhibitor for treating EBV-associated disease.

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

TITLE**"ADOPTIVE IMMUNOTHERAPY"****RELATED APPLICATIONS**

5 **[0001]** This application claims priority to Australian Provisional Application No. 2019903995 entitled "Adoptive Immunotherapy", filed on 23 October 2019, the entire content of which is hereby incorporated by reference in its entirety.

TECHNICAL FIELD

10 **[0002]** This invention relates generally to the field of therapeutic compositions, and methods of adoptive immunotherapy. More particularly, this invention relates to methods of adoptive immunotherapy in subjects with an Epstein-Barr virus (EBV)-associated disease, disorder or condition, such as cancer.

15 **BACKGROUND OF THE INVENTION**

[0003] Adoptive or cellular immunotherapy has emerged as a powerful tool for treating cancer, infectious complications and autoimmune diseases [1]. The first success of T cell therapy in clinic was demonstrated by Steven Rosenberg's group who pioneered in vitro expansion of patient
20 derived tumour-infiltrating cells (TILs) and infused back into advanced stage melanoma patients [2]. Since then, the T cell effector function has been known to demonstrate clinical success against the treatment of drug resistance bacterial and fungal infection [3], viral infections including HIV [4], CMV [5] and BKV [6]; alongside hematological malignancies and EBV-
25 associated post-transplant lymphoproliferative disease (PTLD) in hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) patients [7]. However, the impact of these therapies in gaining an effective and sustained clinical response against solid cancers remains a significant challenge.

30 **[0004]** The mechanism of action associated with effective adoptive cell transfer (ACT) response against cancer revolves around the capacity of T cells to recognize tumour associated antigens (TAAs) presented by HLA

molecules expressed on malignant cells [1]. The TAAs comprise of molecular factors which play critical role in cell proliferation, neoantigens arising from somatic mutations and cancer testes/germline antigens (CTA) which are located at immune privileged sites. *In vitro* expanded T cells from tumour-infiltrating lymphocytes or peripheral blood mononuclear cells have been extensively used. This technique has gained much attention against the treatment of viral-associated cancers and disease of transplant patients. In particular, adoptive T cell therapy has shown remarkable clinical responses against Epstein Barr Virus (EBV) associated posttransplant lymphomas (PTLD) [7]. EBV is a potent human ubiquitous B-lymphotropic oncogenic herpesvirus known to be associated with a wide range of human malignancies.

[0005] In healthy individuals, the EBV infection is controlled immunologically via functional CD8⁺ cytotoxic T lymphocytes (CTL) and CD4⁺ T lymphocytes predominantly recognizing EBNA3-6 antigens expressed in virus-infected B cells [8, 9]. However, due to its ubiquitous nature and persuasive cellular transforming capability, EBV infection is associated with multiple malignancies of both B cell and epithelial cell origin, such as Burkitt's lymphoma (BL), Hodgkin's lymphoma (HL), natural killer or T (NK/T) cells lymphoma, post-transplant lymphoproliferative disease (PTLD), nasopharyngeal carcinoma (NPC) and gastric carcinoma (GC) [10]. To date, radiation and/or chemotherapy remain the primary mainstay for the therapeutic treatment of EBV-associated malignancies. A large number of clinical trials are currently underway using EBV-specific autologous T cell immunotherapy [7]. However, time span required to manufacture and test the safety of autologous CTL prior to administration into the patient has been one of the major limitations on the generation of EBV-specific T cells for ACT.

30

SUMMARY OF THE INVENTION

[0006] The present invention is broadly directed to a method of treating or preventing an EBV-associated disease, disorder or condition, such as an EBV-associated cancer, in a subject by administering allogeneic EBV-specific T cells that bind or recognize an epitope of an EBV antigen thereto.

35

[0007] In a first aspect, the invention provides a method of treating or preventing an EBV-associated disease, disorder or condition in a subject, said method including the steps of:

5 **[0008]** (a) administering to the subject a first population of allogeneic T cells that bind or recognize a first epitope of an EBV antigen; and

[0009] (b) administering to the subject a second population of allogeneic T cells that bind or recognize a second epitope of the EBV antigen or a further EBV antigen;

10 **[0010]** to thereby treat or prevent the EBV-associated disease, disorder or condition in the subject.

[0011] In some embodiments, the method of the present aspect further includes the initial step of generating the first and/or second populations of allogeneic T cells *in vitro*.

15 **[0012]** Suitably, the present method includes the further step of administering a therapeutic agent to the subject. In one embodiment, the therapeutic agent is selected from the group consisting of an immunotherapeutic agent, a MAPK pathway inhibitor, such as a MEK1/2 inhibitor, a BET inhibitor and any combination thereof. In this regard, the
20 immunotherapeutic agent suitably is or comprises an immune checkpoint inhibitor, such as a PD1 inhibitor, a PDL1 inhibitor, a CTLA4 inhibitor, a LAG3 inhibitor, a TIM3 inhibitor or a CD96 inhibitor. In some particular embodiments, the immune checkpoint inhibitor is or comprises an anti-PD1 antibody.

25 **[0013]** In a second aspect, the invention resides in a pharmaceutical composition for treating or preventing an EBV-associated disease, disorder or condition in a subject, the composition comprising:

[0014] a first population of allogeneic T cells that bind or recognize a first epitope of an EBV antigen;

30 **[0015]** a second population of allogeneic T cells that bind or recognize a second epitope of the EBV antigen or a further EBV antigen; and

[0016] optionally a pharmaceutically acceptable carrier, diluent and/or excipient.

[0017] With respect to the aforementioned aspects, the first population of allogeneic T cells and cells of the EBV-associated disease,
5 disorder or condition suitably both comprise or are restricted by a first human leukocyte antigen (HLA) allele that encodes a first MHC protein. In this regard, the first MHC protein may present the first epitope of the EBV antigen on cells of the EBV-associated disease, disorder or condition.

[0018] For the first and second aspects, the second population of
10 allogeneic T cells and cells of the EBV-associated disease, disorder or condition both comprise or are restricted by a second HLA allele that encodes a second MHC protein. To this end, the second MHC protein suitably presents the second epitope of the EBV antigen or the further EBV antigen on cells of the EBV-associated disease, disorder or condition.

[0019] In some embodiments of the aforementioned aspects, the
15 second population of allogeneic T cells is administered prior to, simultaneously with and/or subsequent to administration of the first population of allogeneic T cells.

[0020] In a third aspect, the invention resides in a method of
20 treating or preventing an EBV-associated disease, disorder or condition in a subject, said method including the steps of:

[0021] (a) administering to the subject a population of allogeneic T cells that bind or recognize an epitope of an EBV antigen; and

[0022] (b) administering to the subject a therapeutic agent,
25 wherein the therapeutic agent is selected from the group consisting of an immunotherapeutic agent, a MAPK pathway inhibitor, a BET inhibitor and any combination thereof;

[0023] to thereby treat or prevent the EBV-associated disease, disorder or condition in the subject.

[0024] Suitably, the population of allogeneic T cells is administered
30 prior to, simultaneously with and/or subsequent to administration of the therapeutic agent.

[0025] In some embodiments, the current method further includes the initial step of generating the population of allogeneic T cells *in vitro*.

[0026] In a fourth aspect, the invention provides a pharmaceutical composition for treating or preventing an EBV-associated disease, disorder
5 or condition in a subject, the composition comprising:

[0027] a population of allogeneic T cells that bind or recognize an epitope of an EBV antigen;

[0028] a therapeutic agent, wherein the therapeutic agent is selected from the group consisting of an immunotherapeutic agent, a MAPK
10 pathway inhibitor, a BET inhibitor and any combination thereof; and

[0029] optionally, a pharmaceutically acceptable carrier, diluent and/or excipient.

[0030] Referring to the third and fourth aspects, the population of allogeneic T cells and cells of the EBV-associated disease, disorder or
15 condition suitably both comprise or are restricted by a first human leukocyte antigen (HLA) allele that encodes a first MHC protein. In some embodiments, the MHC protein presents the epitope of the EBV antigen on cells of the EBV-associated disease, disorder or condition.

[0031] Suitably for the third and fourth aspects, the
20 immunotherapeutic agent is or comprises an immune checkpoint inhibitor, such as a PD1 inhibitor, a PDL1 inhibitor, a CTLA4 inhibitor, a LAG3 inhibitor, a TIM3 inhibitor or a CD96 inhibitor. In certain embodiments, the immune checkpoint inhibitor is or comprises an anti-PD1 antibody. In some embodiments, the MAPK pathway inhibitor is or comprises a MEK1/2
25 inhibitor.

[0032] In a fifth aspect, the invention relates to use of a first population of allogeneic T cells that bind or recognize a first epitope of an EBV antigen in the manufacture of a medicament for the treatment or prevention of an EBV-associated disease, disorder or condition in a subject;
30 wherein the first population of allogeneic T cells is to be administered in combination with: (a) a second population of allogeneic T cells that bind or recognize a second epitope of the EBV antigen or a further EBV antigen;

and/or (b) a therapeutic agent, wherein the therapeutic agent is selected from the group consisting of an immunotherapeutic agent, a MAPK pathway inhibitor, a BET inhibitor and any combination thereof.

[0033] In a sixth aspect, the invention provides a first population
5 of allogeneic T cells that bind or recognize a first epitope of an EBV antigen for use in the treatment or prevention of an EBV-associated disease, disorder or condition in a subject; wherein the first population of allogeneic T cells is to be administered in combination with: (a) a second population of allogeneic T cells that bind or recognize a second epitope of the EBV
10 antigen or a further EBV antigen; and/or (b) a therapeutic agent, wherein the therapeutic agent is selected from the group consisting of an immunotherapeutic agent, a MAPK pathway inhibitor, a BET inhibitor and any combination thereof.

[0034] Referring to the aforementioned aspects, the EBV antigen
15 and/or the further EBV antigen is suitably selected from the group consisting of EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, LMP1, LMP2 and any combination thereof. In one embodiment, the EBV antigen and/or the further EBV antigen is or comprises EBNA1, LMP1 and/or LMP2.

[0035] Suitably for the above aspects, the EBV-associated disease,
20 disorder or condition is or comprises an EBV-associated cancer. In certain embodiments, the EBV-associated cancer is selected from the group consisting of nasopharyngeal carcinoma, NKT cell lymphoma, Hodgkin's Lymphoma, post-transplant lymphoproliferative disease, Burkitt's lymphoma, Diffuse large B-cell lymphoma, gastric cancer, and any
25 combination thereof.

[0036] Suitably, the subject of the aforementioned aspects of the invention is a mammal.

[0037] Preferably, the subject is a human.

[0038] Throughout this specification, unless otherwise indicated,
30 "*comprise*", "*comprises*" and "*comprising*" are used inclusively rather than exclusively, so that a stated integer or group of integers may include one or more other non-stated integers or groups of integers.

[0039] It will also be appreciated that the indefinite articles “a” and “an” are not to be read as singular indefinite articles or as otherwise excluding more than one or more than a single subject to which the indefinite article refers. For example, “a” protein includes one protein, one
5 or more proteins or a plurality of proteins.

BRIEF DESCRIPTION OF THE FIGURES

[0040] **Figure 1: Efficacy of allogenic “off-the-shelf” EBV specific T-cells in recognizing and eliminating multiple cancers *in vitro*.** (A) Statistical representation of the relative fold expression at
10 transcript level of indicated EBV-associated genes across respective EBV-associated cancer cell lines compared to NP43 (EBV-) cancer cells. Housekeeping genes, HPRT1 and 18s RNA was used as loading control. (B) FACS plot representing expression of IFN- γ in presence of LMP1/2 and EBNA1 specific peptides observed in the viable CD8+ population across
15 indicated allogenic EBV-specific effector AdE1-LMPpoly transfected T cells as previously described [1]. (C) Statistical representation of cellular cytotoxicity measured by LDH release assay among indicated EBV-associated cancer cell lines highlighting the dose-dependent increase of T cell derived cytotoxicity across varying effector to target cell ratio (5:1-
20 100:1). The cellular cytotoxicity of the HLA-matched T cells is represented as a relative fold change of LDH release after 24 hours of T cell treatment of cancer cells compared to the positive control (detergent lysed control). (D) Statistical representation of the cell viability measured by MTS assay highlighting the impact of a HLA-matched T cells in suppressing cellular
25 growth of multiple EBV-associated cancer cell lines of different origin in a dose-dependent manner across varying effector to target cell ratio (5:1-100:1). SNKT16 (HLA) was treated with both TI_001 and TI_002 and its cell viability was compared to the cell viability SNU719 (HLA) and C17(HLA) respectively. The cell viability of the respective cancer cells is represented
30 as a relative fold change of viable cells after 24 hours of T cell treatment compared to mock (PBS) treated control. (E) Statistical representation of cell death measured by Annexin V binding assay among indicated EBV-associated cancer cell lines in the presence of HLA-matched T cell (50:1 effector to target cell ratio). The cell death among respective cancer cells is
35 represented as the relative fold change of Annexin V binding in T cells treated samples compared to mock (PBS) treated, after 48 hours of T cell

treatment. Error bars represent the $\pm$ SEM from three independent experiments.

[0041] Figure 2: Phenotyping the characteristics of the EBV-associated cancer cells effector T cells *in vitro*. (A) Statistical representation comparing the (i) percentage of Ki67+ population; (ii) percentage of active Caspase 3+ population; and (iii) percentage of BCL2+ population of viable indicated EBV-associated cancer cell lines after 24 hours of mock (PBS) and HLA-matched T cells treatment. SNU719 and C17 were treated with TI_001 and TI_002 T cells respectively while SNKT16 was treated with both the T cells. Both SNU719 and C17 were gated as CD45- population while SNKT16 were gated as CD45+ CD3+ CD56+ population to distinguish out from the T cell population. (B) Statistical representation comparing the (i) percentage of CD8+ population; (ii) percentage of Ki67+ population; (iii) percentage of GnzB+ (Granzyme B) population; (iv) percentage of GnzK+ (Granzyme K) population; (iii) percentage of Perf+ (Perforin) population of viable T cells used to treat respective EBV-associated cancer cell lines as described in (A). Error bars represent the $\pm$ SEM from three independent experiments. P-values were calculated using one-way ANOVA: **p<0.01, and ***p<0.001.

[0042] Figure 3: Assessment of therapeutic efficacy of allogeneic EBV-specific cytotoxic T cells against solid cancers *in vivo*. Statistical representation of tumour growth and percent survival post T cell therapy observed after single dosage of T cells observed in (A) C17 and (B) C666.1 derived tumour xenografts; and double dosage of T cell therapy at an interval of 96 hours (indicated by the black arrows) in (C) C17 and (D) C666.1 derived tumour xenografts. C17 was treated with TI_002 while C666.1. treated with TI_004. Tumour size (area, mm²) was measured using a digital calliper and mean tumour size of each cohort was represented. The tumour growth of each cell line derived xenograft is represented as the mean tumour area $\pm$ SEM from n $\geq$ 4 mice/group. The mice survival was monitored over the indicated period of time and the statistical significance of data was analysed by log-rank test: *p<0.05, **p<0.01, and ***p<0.001.

[0043] Figure 4: Assessment of "switch antigen" therapy provides improved efficacy of the EBV-specific cytotoxic T cells *in*

vivo. (A) Statistical representation of SNU719 derived xenograft indicating (i) tumour growth; (ii) tumour weight (in gms) at ethical limit of tumour growth; (iii) percent survival post T cell therapy observed in T cells treated (two dosage at an interval of 96 hours each) group compared to mock (PBS) treated control group. (B) Statistical representation of SNU719 derived xenograft indicating (i) tumour growth; (ii) tumour weight (in gms) at ethical limit of tumour growth; (iii) percent survival post T cell therapy observed in T cells treated (three dosage) group compared to mock (PBS) treated control group. The red arrow indicates administration of three continuous dosage (at an interval of 96 hours each) of TI_001 while the green arrow indicates switching the third dose to TI_004, which was administered after two dosage of TI_001. The tumour growth of each cell line derived xenograft is represented as the mean tumour area $\pm$ SEM from $n \geq 5$ mice/group. The statistical significance of data of tumour weight was analysed by Mann-Whitney t- test. The mice survival was monitored over the indicated period of time and the statistical significance of data was analysed by log-rank test: ** $p < 0.01$, *** $p < 0.001$, and **** $p < 0.0001$.

[0044] Figure 5: Assessment of therapeutic efficacy of allogeneic EBV-specific cytotoxic T cells against lymphoid malignancies *in vivo*. (A) Schematic diagram demonstrating the reconstitution schedule of the human immune system over 12 weeks in NRG mice using CD34+ cells post irradiation and mice monitoring for graft versus host disease (GVHD). The schematics also illustrates the EBV virus was administered (QIMR-WIL strain), post-reconstitution and was monitored for 2 weeks for EBV incubation. HLA-matched T cells were administered on the indicated days (highlighted by red arrows) post-EBV infection and the mice were sacrificed 2 weeks after T cell therapy. (B) Statistical representation highlighting the reconstitution of the human immune system over 12 weeks as indicated by presence of percentage of viable (i) CD45+; (ii) CD45+ CD3+; and (iii) CD45+ CD19+ population across respective groups. (C) Gross morphology of spleen illustrating the size and presence of lymphoid malignancies in the spleen of $n = 3$ mice reconstituted with CB33A CD34+ cord blood cells across respective treatment groups. G1 represents administration of three continuous dosage (at an interval of 96 hours each) of TI_005 while G2 indicates switching the third dose to TI_002, which was administered after two dosage of TI_005. (D) Statistical representation

comparing spleen weight (in gms) across respective treatment groups. (E) Gross morphology of spleen illustrating the size and presence of lymphoid malignancies in the spleen of $n = 3$ mice reconstituted with CB03 CD34+ cord blood cells across respective treatment groups. G1 was treated with
 5 TI_002 while G2 was treated with TI_003 as per strategy indicated in (C). (F) Statistical representation comparing spleen weight (in gms) across respective treatment groups. The statistical significance of data of tumour weight was analysed by one-way ANOVA: $**p < 0.01$, and $***p < 0.001$.

[0045] Figure 6: Impact of PD1 inhibition on therapeutic
 10 **efficacy of allogeneic EBV-specific cytotoxic T cells *in vivo*.** (A) Heat-map representing gene signature of 326 genes observed RNA isolated from in the tumour infiltrating (TILs) CD8+ cells performed using NanoString Immune function panel. The TILs were isolated from SNU719 derived tumour xenograft from six independent mice (LT5-10) after 5 days post a
 15 single dose of TI_001 treatment when the tumour size reached 40 mm². The gene expression observed in TILs was compared to unstimulated (LT11) and EBV-pepmix stimulated (LT12). (B) Statistical representation comparing the (i) percentage of CD3+CD8+ population; (ii) percentage of CD8+PD1+ population; (iii) percentage of CD8+LAG3+ population; and (iv)
 20 percentage of CD8+ TIM3+ population of viable TILs (described in (A)) and compared to unstimulated T cells (T cell therapy). Error bars represent the $\pm$ SEM from three independent experiments. P-values were calculated using one-way ANOVA. Statistical representation of SNU719 derived xenograft indicating (C) tumour growth; (D) tumour weight (in gms) at ethical limit
 25 of tumour growth; (E) percent survival post T cell, anti-PD1 and combination of T cell and anti-PD1 therapy observed in respective treatment groups compared to mock (PBS) treated control group. The statistical significance of data of tumour weight was analysed by one-way ANOVA. The mice survival was monitored over the indicated period of time and the
 30 statistical significance of data was analysed by log-rank test: ns not significant, $**p < 0.01$, $***p < 0.001$, and $****p < 0.0001$.

[0046] Figure 7: Combination of MEK/12 inhibitors with EBV-specific T cells. (A) Statistical representation of the cell viability measured by MTS assay highlighting the impact of a HLA-matched EBV specific T cells
 35 and MEK1/2 inhibitors (AZD6244 and trametinib) in suppressing cellular growth individually and in combination after 48hrs of incubation with

SNU719 cells. (B) Statistical representation of cell death measured by Annexin V binding assay observed in presence EBV specific T cells and MEK1/2 inhibitors as individual and combination treatment highlighting the level of cell death observed after 48hrs of incubation with SNU719 cells. (C) Growth curve highlight the rate of cellular death observed in the presence of HLA-matched EBV specific T cells and MEK1/2 inhibitors individually and in combination using Xceligence. P-values were calculated using one-way ANOVA: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ and **** $p < 0.0001$.

[0047] Figure 8: Combination of JQ1 with EBV-specific T cells. (A) Statistical representation of the cell viability measured by MTS assay highlighting the impact of a HLA-matched EBV specific T cells and JQ1 in suppressing cellular growth individually and in combination after 48 hrs of incubation with SNU719 cells. (B) Statistical representation of cell death measured by Annexin V binding assay observed in presence EBV specific T cells and JQ1 as individual and combination treatment highlighting the level of cell death observed after 48 hrs of incubation with SNU719 cells. P-values were calculated using one-way ANOVA: ns- not significant, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ and **** $p < 0.0001$.

[0048] Figure 9: Determining the IC₅₀ value of MEK1/2 inhibitors. Representation of the cell viability performed using MTS assay after the indicated cell lines were incubated with 0.1 μ M-5 μ M of selumatinib (left panel) and trametinib (right panel) for 48 hours. The data are represented as the mean $\pm$ SD from three independent experiments.

[0049] Figure 10: Combination of MEK1/2 inhibitors with HLA matched allogeneic EBV-specific T cells. The cell viability measured by MTS assay highlighting the impact of a HLA-matched EBV specific T cells at the effector-to-target ratio of 25:1 and MEK1/2 inhibitors selumatinib (upper panel) and trametinib (lower panel) at a concentration of 1 μ M in suppressing cellular growth individually and in combination after 48hrs of incubation with indicated (A) C17; (B) C666.1; (C) SNU719 and (D) YCCLE1. The data are represented as the mean $\pm$ SD from three independent experiments. *P-values* were calculated using one-way ANOVA: ns= not significant, * = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.001$ and **** = $p < 0.0001$.

[0050] Figure 11: Impact of dual combination of MEK1/2 inhibitor and HLA matched allogeneic EBV-specific T cells. (A) Cell growth curve highlight the rate of cellular proliferation of SNU719 (upper panel) and C666.1 (lower panel) observed in the presence of HLA-matched EBV specific T cells (effector-to-target ratio of 25:1) and selumatinib (1 μ M) individually and in combination, measured using Xcellegence. The effect of individual and dual combination on (B) cell proliferation based on Ki67 and (C) cell death based on active Caspase-3 of SNU719 expression (upper panel) and C666.1 (lower panel), performed using flow cytometry. The data are represented as the mean $\pm$ SD from three independent experiments. *P-values* were calculated using one-way ANOVA: ns= not significant, **p*<0.05, ***p*<0.01, ****p*<0.001 and *****p*<0.0001.

[0051] Figure 12: Combination of MEK1/2 inhibitors with HLA mismatched allogeneic-specific T cells. The cell viability measured by MTS assay highlighting the impact of a HLA-mismatched specific T cells at the effector-to-target ratio of 25:1 and MEK1/2 inhibitors (A) selumatinib and (B) trametinib at a concentration of 1 μ M in suppressing cellular growth individually and in combination after 48 hrs of incubation with SNU719 (upper panel) and C666.1 (lower panel). (C) The cell viability measured by MTS assay comparing the effect of HLA-matched and HLA-mismatched EBV-specific T cells (at the effector-to-target ratio of 25:1) alone and in combination with selumatinib and trametinib (1 μ M) when incubated with SNU719 (upper panel) and C666.1 (lower panel). The data are represented as the mean $\pm$ SD from three independent experiments. *P-values* were calculated using one-way ANOVA: ns= not significant, * = *p*<0.05, ** = *p*<0.01, *** = *p*<0.001 and **** = *p*<0.0001.

[0052] Figure 13: Phenotyping the impact of dual combination of MEK1/2 inhibitor and HLA matched allogeneic EBV-specific T cells on cancer cell intrinsic pathways. Representation of the cancer cell phenotype after 16 hours of individual and dual combination of selumatinib (1 μ M) and HLA-matched EBV specific T cells (effector-to-target ratio of 25:1) among SNU719 (upper panel) and C666.1 (lower panel) on the expression of (A) pERK1/2; (B) MHC-Class I; (C) pSTAT3; and (D) MYC performed using flow cytometry. The data are represented as the mean $\pm$ SD from three independent experiments. *P-values* were calculated using

one-way ANOVA: ns= not significant, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ and **** $p < 0.0001$.

[0053] Figure 14: Determining the IC₅₀ value of JQ1 inhibitors. Representation of the cell viability performed using MTS assay after the indicated cell lines were incubated with 0.5 μ M-10 μ M of JQ1 for 48 hours. The data are represented as the mean $\pm$ SD from three independent experiments.

[0054] Figure 15: Impact of dual combination of JQ1 inhibitor and HLA matched allogeneic EBV-specific T cells. The cell viability measured by MTS assay highlighting the impact of a HLA-matched EBV specific T cells at the effector-to-target ratio of 25:1 and JQ1 (2.5 μ M) in suppressing cellular growth individually and in combination after 48 hrs of incubation with indicated (A) gastric (SNU719, YCCLE1 (upper panel)) and nasopharyngeal cancer cells (C17, C666.1 (lower panel)). (B) Cell growth curve highlight the rate of cellular proliferation of SNU719 (upper panel) and C666.1 (lower panel) observed in the presence of HLA-matched EBV specific T cells (effector-to-target ratio of 25:1) and JQ1 (2.5 μ M) individually and in combination, measured using Xcellegence. The effect of individual and dual combination on (C) cell proliferation based on Ki67 and (D) cell death based on active Caspase-3 of SNU719 expression (upper panel) and C666.1 (lower panel), performed using flow cytometry. The data are represented as the mean $\pm$ SD from three independent experiments. *P-values* were calculated using one-way ANOVA: ns= not significant, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ and **** $p < 0.0001$.

[0055] Figure 16: Combination of JQ1 inhibitors with HLA mismatched allogeneic-specific T cells. (A) The cell viability measured by MTS assay highlighting the impact of a HLA-mismatched specific T cells at the effector-to-target ratio of 25:1 and JQ1 inhibitor at a concentration of 2.5 μ M in suppressing cellular growth individually and in combination after 48 hrs of incubation with SNU719 (upper panel) and C666.1 (lower panel). (B) The cell viability measured by MTS assay comparing the effect of HLA-matched and HLA-mismatched EBV-specific T cells (at the effector-to-target ratio of 25:1) alone and in combination with JQ1 inhibitor (2.5 μ M) when incubated with SNU719 (upper panel) and C666.1 (lower panel). The data are represented as the mean $\pm$ SD from three independent

experiments. *P-values* were calculated using one-way ANOVA: ns= not significant, * = $p<0.05$, ** = $p<0.01$, *** = $p<0.001$ and **** = $p<0.0001$.

5 **[0056] Figure 17: Phenotyping the impact of dual combination of JQ1 inhibitor and HLA matched allogeneic EBV-specific T cells on cancer cell intrinsic pathways.** Representation of the cancer cell phenotype after 16 hours of individual and dual combination of JQ1 (2.5 μ M) and HLA-matched EBV specific T cells (effector-to-target ratio of 25:1) among SNU719 (upper panel) and C666.1 (lower panel) on the
10 expression of (A) MYC; (B) pERK1/2; (C) pAKT; and (D) pSTAT3 performed using flow cytometry. The data are represented as the mean $\pm$ SD from three independent experiments. *P-values* were calculated using one-way ANOVA: ns= not significant, * $p<0.05$, ** $p<0.01$, *** $p<0.001$ and **** $p<0.0001$.

15 **[0057] Figure 18: Phenotyping the impact of dual combination of JQ1 inhibitor and HLA matched allogeneic EBV-specific T cells on immune regulatory molecules.** Representation of the cancer cell phenotype after 16 hours of individual and dual combination of JQ1 (2.5 μ M) and HLA-matched EBV specific T cells (effector-to-target ratio
20 of 25:1) among SNU719 (upper panel) and C666.1 (lower panel) on the expression of (A) MHC Class-I; (B) PD-L1; and (C) CD47 performed using flow cytometry. The data are represented as the mean $\pm$ SD from three independent experiments. *P-values* were calculated using one-way ANOVA: ns= not significant, * $p<0.05$, ** $p<0.01$, *** $p<0.001$ and **** $p<0.0001$.

25 **[0058] Figure 19: Assessment of therapeutic efficacy of dual combination of selumatinib and allogeneic EBV-specific cytotoxic T cells *in vivo*.** (A) The impact of the dual combination of selumatinib and allogeneic T cells (TIG-001) on the outgrowth of EBV-positive SNU719 xenografts in NRG mice was assessed. Tumour-bearing mice were treated
30 with two doses of HLA-matched T cells (2×10^7 T cells per dose per mouse indicated by black arrow) and selumatinib (12.5 mg/Kg) orally for continuous 14 days, either individually or in combination. The growth of each xenograft is represented as the mean tumour area $\pm$ SD from $n=9$ mice/group. (B) Gross morphology of the tumours isolated from the mice of
35 indicated treatment groups. (C) Representation of tumour weight described

in (B) from the mice of indicated treatment groups. The data are represented as the mean $\pm$ SD from n=3 mice per group. *P-values* were calculated using one-way ANOVA. (D) Representation of viable percentage of tumour infiltrates observed across individually treated allogeneic T cells (TIG-001) and in combination with selumatinib as determined by CD45, CD3 and CD8 expression using flow cytometry. *P-values* were calculated using *Student T test*. (E) Kaplan–Meier overall survival analysis of the mice bearing EBV-associated tumours as described in (A) following individual and combination treatment of selumatinib and allogeneic T cells. The animals' survival (n = 6 mice/group) was monitored over the indicated period of time and statistical significance was analysed by log-rank test: ns= not significant, *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001.

DETAILED DESCRIPTION OF THE INVENTION

15

[0059] The present invention is at least partly predicated on the surprising discovery that adoptive immunotherapy with “off-the-shelf” allogeneic EBV-specific T-cells is capable of treating or preventing a range of EBV-associated or EBV-positive cancers. This therapeutic effect has been shown to be particularly effective when a combination of EBV-specific T cell populations that are specific for different EBV antigen epitopes are used. Additionally, the present inventors have demonstrated that the combination of allogeneic EBV-specific T cells and an immune checkpoint inhibitor, a MEK1/2 inhibitor and/or a BET inhibitor could significantly improve the efficacy of such adoptive T cell therapy against EBV-associated diseases, disorders or conditions.

[0060] Accordingly, in a broad form, the present invention relates to a method of treating or preventing an EBV-associated disease, disorder or condition in a subject, said method including the step of administering a population of allogeneic T cells that bind or recognize an epitope of an EBV antigen to the subject to thereby treat or prevent the EBV-associated disease, disorder or condition in the subject.

[0061] In an aspect, the present invention relates to a method of treating or preventing an EBV-associated disease, disorder or condition in a subject, said method including the steps of:

[0062] (a) administering to the subject a therapeutically effective amount of a first population of allogeneic T cells that bind or recognize a first epitope of an EBV antigen; and

5 **[0063]** (b) administering to the subject a therapeutically effective amount of a second population of allogeneic T cells that bind or recognize a second epitope of the EBV antigen or a further EBV antigen;

[0064] to thereby treat or prevent the EBV-associated disease, disorder or condition in the subject.

10 **[0065]** In a related aspect, the invention provides a pharmaceutical composition for treating or preventing an EBV-associated disease, disorder or condition in a subject, the composition comprising:

[0066] a first population of allogeneic T cells that bind or recognize a first epitope of an EBV antigen;

15 **[0067]** a second population of allogeneic T cells that bind or recognize a second epitope of the EBV antigen or a further EBV antigen; and

[0068] optionally a pharmaceutically acceptable carrier, diluent and/or excipient.

20 **[0069]** The statements which follow apply equally to the two aforementioned aspects.

[0070] Epstein-Barr Virus or EBV is a common human pathogen and may cause, or be associated with, one or more diseases, disorders or conditions in humans. Thus, certain embodiments of the aforementioned methods relate to preventing and/or treating one or more diseases, disorders or conditions caused by, or associated with, an EBV infection in humans, such as an EBV-associated cancer. EBV predominantly infects human hosts through epithelial cells and B lymphocytes where it can then establish long-term latency in the human host. Primary infection of EBV causes over 90% of cases of infectious mononucleosis (IM) worldwide, infecting mainly children and young adults through the expansion of EBV infected B cells. EBV has also been associated with several cancers, including Burkitt and Hodgkin's lymphomas, gastric and nasopharyngeal

25
30

carcinomas, lymphomas in HIV-infected individuals and post-transplant lymphoproliferative disorder (PTLD). EBV has also been found to be implicated in autoimmune diseases, particularly multiple sclerosis.

[0071] In the context of the present invention, by "*EBV-associated disease, disorder or condition*" is meant any clinical pathology resulting from or link to an infection by an Epstein Barr virus. To this end, EBV-associated disease, disorder or condition can mean any disease caused, directly or indirectly, by EBV as well as diseases which predispose a patient to infection by EBV. Examples of diseases falling into the former category include infectious mononucleosis, nasopharyngeal carcinoma, and Burkitt's lymphoma. Diseases in the latter category (i.e., those which place the patient at risk of EBV infection) include acquired immune deficiency syndrome and, generally, any condition that causes a state of immunosuppression or decreased function of the immune system such as patients who receive organ transplants and certain cancer therapies. In one particular embodiment, the EBV-associated disease, disorder or condition suitably is or comprises multiple sclerosis.

[0072] The term "*EBV-positive cells*" refers to those cells, inclusive of cancer cells, which express EBV or one or more EBV proteins, such as in a latent form.

[0073] In preferred embodiments, the EBV-associated disease, disorder or condition is or comprises an EBV-associated and/or -positive cancer. As used herein, and unless otherwise specified, the term "*EBV-associated cancer*" or "*EBV-positive cancer*" refers to a cancer that has been linked to the Epstein-Barr virus (EBV). In certain embodiments, EBV-positive cancers are cancers wherein greater than about 30%, greater than about 40%, greater than about 50%, greater than about 60%, greater than about 70%, or greater than about 80% contain or express the EBV virus.

[0074] As generally used herein, the terms "*cancer*", "*tumour*", "*malignant*" and "*malignancy*" refer to diseases or conditions, or to cells or tissues associated with the diseases or conditions, characterized by aberrant or abnormal cell proliferation, differentiation and/or migration often accompanied by an aberrant or abnormal molecular phenotype that includes one or more genetic mutations or other genetic changes associated

with oncogenesis, expression of tumour markers, loss of tumour suppressor expression or activity and/or aberrant or abnormal cell surface marker expression.

[0075] Cancers may include any aggressive or potentially aggressive cancers, tumours or other malignancies such as listed in the NCI Cancer Index at <http://www.cancer.gov/cancertopics/alphalist>, including all major cancer forms such as sarcomas, carcinomas, lymphomas, leukaemias and blastomas, although without limitation thereto. These may include breast cancer, lung cancer inclusive of lung adenocarcinoma, cancers of the reproductive system inclusive of ovarian cancer, cervical cancer, uterine cancer and prostate cancer, cancers of the brain and nervous system, head and neck cancers, gastrointestinal cancers inclusive of colon cancer, colorectal cancer and gastric cancer, liver cancer, kidney cancer, skin cancers such as melanoma and skin carcinomas, blood cell cancers inclusive of lymphoid cancers and myelomonocytic cancers, cancers of the endocrine system such as pancreatic cancer and pituitary cancers, musculoskeletal cancers inclusive of bone and soft tissue cancers, although without limitation thereto. In particular embodiments, the cancer is a solid cancer or a leukaemia or liquid cancer. Suitably, the cancer expresses, such as overexpresses, one or more EBV antigens, such as those hereinbefore described.

[0076] In particular embodiments, the EBV-associated cancer is selected from the group consisting of nasopharyngeal carcinoma, NKT cell lymphoma, Hodgkin's Lymphoma, post-transplant lymphoproliferative disease, Burkitt's lymphoma, Diffuse large B-cell lymphoma, gastric cancer, parotid carcinoma, breast carcinoma, leiomyosarcoma and any combination thereof. In a specific embodiment, the EBV-associated cancer is not post-transplant lymphoproliferative disease.

[0077] As used herein, by "*isolated*" is meant material that has been removed from its natural state or otherwise been subjected to human manipulation. Isolated material may be substantially or essentially free from components that normally accompany it in its natural state, or may be manipulated so as to be in an artificial state together with components that normally accompany it in its natural state. Isolated material may be in

recombinant, chemical synthetic, enriched, purified or partially purified form.

[0078] As used herein, "*treating*", "*treat*" or "*treatment*" refers to a therapeutic intervention that at least partly ameliorates, eliminates or
5 reduces a symptom or pathological sign of an EBV-associated disease, disorder or condition after it has begun to develop. Treatment need not be absolute to be beneficial to the subject.

[0079] As used herein, "*preventing*", "*prevent*" or "*prevention*" refers to a course of action initiated prior to infection by, or exposure to,
10 EBV or molecular components thereof and/or before the onset of a symptom or pathological sign of an EBV-associated disease, disorder or condition, so as to at least partly prevent and/or reduce the symptom or pathological sign. It is to be understood that such prevention need not be absolute or complete to be beneficial to a subject.

[0080] The term "*therapeutically effective amount*" describes a
15 quantity of a specified agent, such as EBV-specific allogeneic T cells or therapeutic agent, sufficient to achieve a desired effect in a subject being treated with that agent. For example, this can be the amount of a composition comprising the first population of allogeneic T cells, the second
20 population of allogeneic T cells and/or the therapeutic agent described herein, necessary to reduce, alleviate and/or prevent an EBV-associated disease, disorder or condition, inclusive of EBV-associated cancer, cancer metastasis and recurrence. In some embodiments, a "*therapeutically effective amount*" is sufficient to reduce or eliminate a symptom of an EBV-
25 associated disease, disorder or condition. In other embodiments, a "*therapeutically effective amount*" is an amount sufficient to achieve a desired biological effect, for example, an amount that is effective to decrease or prevent EBV-associated cancer growth, recurrence and/or metastasis.

[0081] Ideally, a therapeutically effective amount of an agent is an
30 amount sufficient to induce the desired result without causing a substantial cytotoxic effect in the subject. The effective amount of an agent useful for reducing, alleviating and/or preventing an EBV-associated disease, disorder or condition will be dependent on the subject being treated, the type and

severity of any associated disease, disorder and/or condition (e.g., the type of EBV-associated disease, disorder or condition), and the manner of administration of the therapeutic composition.

[0082] It will be appreciated that the method of the present aspect
5 may include one or more further treatments, such as cancer treatments, in addition to those recited above. Such treatments may include drug therapy, chemotherapy, antibody, nucleic acid and other biomolecular therapies, radiation therapy, surgery, nutritional therapy, relaxation or meditational therapy and other natural or holistic therapies, although without limitation
10 thereto. Generally, drugs, biomolecules (e.g., antibodies, inhibitory nucleic acids such as siRNA) or chemotherapeutic agents are referred to herein as "*anti-cancer therapeutic agents*" or "*anti-cancer agents*".

[0083] By "*administering*" or "*administration*" is meant the introduction of an allogeneic T cell and/or therapeutic agent or composition
15 disclosed herein into an animal subject by a particular, chosen route.

[0084] Administration of the allogeneic T cells and/or therapeutic agents, or a composition comprising same may be by any known parenteral, topical or enteral route inclusive of intravenous, intramuscular, intraperitoneal, intracranial, transdermal, oral, intranasal, anal and intra-
20 ocular, although without limitation thereto.

[0085] Dosage forms include tablets, dispersions, suspensions, injections, solutions, syrups, troches, capsules, suppositories, aerosols, transdermal patches and the like. These dosage forms may also include injecting or implanting controlled releasing devices designed specifically for
25 this purpose or other forms of implants modified to act additionally in this fashion. Controlled release of the therapeutic agent may be effected by coating the same, for example, with hydrophobic polymers including acrylic resins, waxes, higher aliphatic alcohols, polylactic and polyglycolic acids and certain cellulose derivatives such as hydroxypropylmethyl cellulose. In
30 addition, the controlled release may be effected by using other polymer matrices, liposomes and/or microspheres.

[0086] Compositions of the present invention suitable for oral or parenteral administration may be presented as discrete units such as capsules, sachets or tablets each containing a pre-determined amount of

one or more therapeutic agents of the invention, as a powder or granules or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion or a water-in-oil liquid emulsion. Such compositions may be prepared by any of the methods of pharmacy, but all methods include the step of bringing into association one or more agents as described above with the carrier which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the agents of the invention with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.

[0087] The allogeneic T cells, therapeutic agents and compositions described herein may be administered in a manner compatible with the dosage formulation, and in such amount as is pharmaceutically-effective. The dose administered to a patient, in the context of the present invention, should be sufficient to effect a beneficial response in a patient over an appropriate period of time. The quantity of agent(s) to be administered may depend on the subject to be treated inclusive of the age, sex, weight and general health condition thereof, factors that will depend on the judgement of the practitioner.

[0088] In certain embodiments, the methods of treating an EBV-associated disease, disorder or condition as described herein comprise administering at least 2 doses (e.g., 2, 3, 4, 5, 6 etc doses) of the first and/or second populations of allogeneic T cells and or the therapeutic agents to the subject. Such doses may be administered in a periodic manner, such as daily, weekly, fortnightly, monthly etc as required.

[0089] One particular broad application of the present invention is the provision of methods of performing cellular or adoptive immunotherapy in a subject having an EBV-associated disease, disorder or condition, such as those hereinbefore described, said method including the step of administering a therapeutically effective amount of an allogeneic T cell described herein and optionally a pharmaceutically acceptable carrier, diluent or excipient to the subject.

[0090] The terms "*cellular immunotherapy*" or "*adoptive immunotherapy*" denote the transfer of immunocompetent cells, such as T-

cells, for the treatment of cancer or infectious diseases (see, e.g., June, C. H., ed., 2001, In: Cancer Chemotherapy and Biotherapy: Principles and Practice, Lippincott Williams & Wilkins, Baltimore; Vonderheide et al., 2003, Immun. Research 27:1-15). To this end, it will be understood that adoptive
5 immunotherapy is a strategy typically aimed at replacing, repairing, or enhancing the biological function of a tissue or system, such as the immune system, by means of autologous or allogeneic cells, such as T-cells.

[0091] As used herein, the term "*allogeneic*" refers to cells or tissues, such as T cells, derived from individuals belonging to the same
10 species but genetically different, and are therefore generally immunologically incompatible. Thus, the term "*allogeneic cells*" refers to cell types that are antigenically distinct, yet belonging to the same species. Typically, the term "*allogeneic*" is used to define cells, such as T cells, that are transplanted from a donor to a recipient of the same species.

[0092] As used herein, the term "*T cell*" (i.e., T lymphocyte) is
15 intended to include all cells within the T cell lineage, including thymocytes, immature T cells, mature T cells and the like, from a mammal (e.g., human). The various T cell populations, such as helper T cells, regulatory T cells, cytotoxic T cells, natural killer T cells and memory T cells, can be defined
20 based on their cytokine profiles and their function. Preferably, T cells are mature T cells that express either CD4 or CD8, but not both, and a T cell receptor. It will be understood that a T cell receptor (TCR) is the molecule found on the surface of T cells that is responsible for recognizing antigenic peptides bound to MHC or HLA molecules. Suitably, the allogeneic T cells
25 comprise CD4+ helper T cells and/or a CD8+ cytotoxic T cells. In this regard, the allogeneic T-cells described herein may be in a mixed population of CD4+ helper T cell/CD8+ cytotoxic T cells.

[0093] According to the invention, a population of allogeneic T
cells, such as a first and/or second population of allogeneic T cells,
30 comprising EBV-specific T cells is administered to the human patient. The population of allogeneic T cells that is administered to the human patient is suitably restricted by an HLA allele shared with EBV-positive cells of the EBV-associated disease, disorder or condition. In one particular
embodiment, the first population of allogeneic T cells and cells of the EBV-
35 associated disease, disorder or condition both comprise, share or are

restricted by a first human leukocyte antigen (HLA) allele that encodes a first MHC protein. In another embodiment, the second population of allogeneic T cells and cells of the EBV-associated disease, disorder or condition both comprise or are restricted by a second HLA allele that encodes a second MHC protein. In some embodiments, this HLA allele restriction is ensured by ascertaining the HLA assignment of cells, such as cancer cells, of the EBV-associated disease, disorder or condition, and selecting a population of allogeneic T cells comprising EBV-specific T cells (or a T cell line from which to derive the population of allogeneic T cells) restricted by an HLA allele of such cells. The HLA assignment (i.e., the HLA loci type) can be ascertained (i.e., typed) by any method known in the art. Non-limiting exemplary methods for ascertaining the HLA assignment can be found in ASHI Laboratory Manual, Edition 4.2 (2003), which is incorporated by reference herein.

15 **[0094]** In certain embodiments, the first and/or second population of allogeneic T cells share one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8 HLA alleles) HLA alleles (e.g., HLA-A alleles, HLA-B alleles, HLA-C alleles, and/or HLA-DR alleles) with EBV-positive cells of the EBV-associated disease, disorder or condition. In this regard, it is envisaged that the first and second population of allogeneic T cells can share one or more of the same HLA alleles with cells of the EBV-associated disease, disorder or condition. Indeed, in particular embodiments, the first population of allogeneic T cells share one or more HLA alleles (e.g., 1, 2, 3, 4, 5, 6, 7, 8 HLA alleles) with the second population of allogeneic T cells. Ideally, the first population of allogeneic T cells suitably comprises one or more HLA alleles, such as the first HLA allele, that are shared with cells of the EBV-associated disease, disorder or condition that are also not shared with (i.e., are different to) those HLA alleles, such as the second HLA allele, of the second population of allogeneic T cells. Similarly, the second population of allogeneic T cells suitably comprises one or more HLA alleles, such as the second HLA allele, that are shared with cells of the EBV-associated disease, disorder or condition that are also not shared with (i.e., are different to) those HLA alleles, such as the first HLA allele, comprised by the first population of allogeneic T cells. To this end, the first and second population of allogeneic T cells preferably do not possess or comprise the same or identical complement of HLA alleles. Furthermore, the first population of allogeneic

T cells suitably do not recognise or bind the second epitope and/or the second population of allogeneic T cells suitably do not recognise or bind the first epitope.

[0095] As used herein, the term "*major histocompatibility complex*" (MHC) refers to an antigen presentation molecule, protein or polypeptide that functions as part of the immune system to bind antigens and other peptide fragments and display them on the cell surface for recognition by antigen recognition molecules such as TCR. MHC may be used interchangeably with the term "*human leukocyte antigen*" (HLA) when used in reference to human MHC; thus, MHC refers to all HLA subtypes including, but not limited to, the classical MHC alleles or genes disclosed herein: HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-DM, HLA-DO, HLA-DP, HLA-DQ, and HLA-DR, in addition to all variants, isoforms, isotypes, and other biological equivalents thereof. MHC class I (MHC-I) and MHC class II (MHC-II) molecules utilize distinct antigen processing pathways. In general, peptides derived from intracellular antigens are presented to CD8+ T cells by MHC class I molecules, which are expressed on virtually all cells, while extracellular antigen-derived peptides are presented to CD4+ T cells by MHC-II molecules. However, several exceptions to this general principle have been observed.

[0096] In certain embodiments disclosed herein, a particular EBV-specific antigen, peptide, and/or epitope is identified and presented in an antigen-MHC complex in the context of an appropriate MHC class I or II protein on cells of the EBV-associated disease, disorder or condition. By way of example, the first MHC protein suitably presents the first epitope of the EBV antigen on cells of the EBV-associated disease, disorder or condition for recognition by the first population of allogeneic T cells, whilst the second MHC protein can present the second epitope of the EBV antigen or the further EBV antigen on cells of the EBV-associated disease, disorder or condition for recognition by the second population of allogeneic T cells. In view of the foregoing, the genetic makeup of the allogeneic T cells described herein may be assessed to determine which HLA/MHC allele is suitable for a particular subject and/or EBV-associated disease, disorder or condition with a particular set of EBV antigens.

[0097] Suitably, the EBV antigen and/or the further EBV antigen may be any as are known in the art. Exemplary EBV antigens include the proteins EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, LMP1 and LMP2. In particular embodiments, the EBV antigen and/or the further EBV antigen is
5 or comprises EBNA1, LMP1 and/or LMP2.

[0098] The allogeneic T cells described herein suitably have antigen specificity for the EBV antigen and/or the further EBV antigen. The phrases "*have antigen specificity*" and "*elicit antigen-specific response*" as used herein means that the allogeneic T cells can specifically bind to and
10 immunologically recognize an antigen, such that binding of the allogeneic T cells to the antigen elicits an immune response. Without being bound to a particular theory or mechanism, it is believed that by eliciting an antigen-specific response against EBV-positive cells of the EBV-associated disease, disorder or condition, the EBV-specific allogeneic T cells described herein
15 can provide for one or more of any of the following: targeting and destroying EBV-positive cells, such as EBV-positive cancer cells, reducing or eliminating cancer cells, facilitating infiltration of immune cells to tumour site(s), and enhancing/extending anti-cancer responses.

[0099] As generally used herein, an "*epitope*" is an antigenic
20 protein fragment that comprises a continuous or discontinuous sequence of amino acids of a protein, wherein the epitope can be recognized or bound by an element of the immune system, such as an antibody or other antigen receptor, such as an MHC protein. It will be well understood by a skilled artisan that most EBV antigens can have multiple epitopes or antigenic
25 determinants.

[0100] In view of the foregoing, the first epitope can be an antigenic protein fragment of an EBV protein, whilst the second epitope is suitably a different antigenic protein fragment from the same EBV protein from which the first epitope is derived or a further EBV protein.

[0101] As used herein a "*protein*" is an amino acid polymer, wherein the amino acids may include D-amino acids, L-amino acids, natural and/or non-natural amino acids. As typically used herein, a "*peptide*" is a protein comprising no more than sixty (60) contiguous amino acids. As typically used herein, a "*polypeptide*" is a protein comprising more than
30

sixty (60) contiguous amino acids. The term "*protein*" should also be understood to encompass protein-containing molecules such as glycoproteins and lipoproteins, although without limitation thereto.

[0102] In some embodiments, the allogeneic T cells and/or the
5 therapeutic agents described herein, inclusive of combinations of these, may be administered to a subject in the form of a composition comprising a pharmaceutically acceptable carrier, diluent or excipient.

[0103] It will be appreciated that pharmaceutically acceptable carriers, diluents and/or excipients may include any solid, semi-solid, gel or
10 liquid fillers, diluents or encapsulating substances that may be safely used in systemic administration. Depending upon the particular route of administration, carriers, diluents and/or excipients may be selected from a group including sugars, starches, cellulose and its derivatives, malt, gelatine, talc, calcium sulphate, vegetable oils, synthetic oils, polyols,
15 alginic acid, isotonic saline, pyrogen-free water, wetting or emulsifying agents, bulking agents, glidants, coatings (e.g., enteric coatings), emollients, binders, fillers, disintegrants, lubricants, pH buffering agents (e.g. phosphate buffers) and/or flavouring agents, although without limitation thereto. The composition may be administered to a human in any
20 one or more dosage forms that include tablets, dispersions, suspensions, injectable solutions, syrups, troches, capsules, suppositories, aerosols, transdermal patches and the like.

[0104] A useful reference describing pharmaceutically acceptable carriers, diluents and excipients is Remington's Pharmaceutical Sciences
25 (Mack Publishing Co. N.J. USA, 1991) which is incorporated herein by reference.

[0105] In particular embodiments, the second population of allogeneic T cells is administered (i) prior to; (ii) after; or (iii) simultaneously with, the administration of the first population of allogeneic
30 T cells. In one embodiment, administration of the first population of allogeneic T cells, and administration of the second population of allogeneic T cells (either sequentially or concurrently) results in treatment or prevention of an EBV-associated disease, disorder or condition that is greater than such treatment or prevention from administration of either the

first population of allogeneic T cells or the second population of allogeneic T cells in the absence of the other.

[0106] In particular embodiments, the above method further includes the initial step of generating the first and/or second populations of
5 allogeneic T cells *in vitro*. The first and second populations of allogeneic T cells comprising EBV-specific T cells that are administered to the human patient can be generated by a method known in the art, or can be selected from a pre-existing bank (collection) of cryopreserved T cell lines (each T cell line comprising EBV-specific T cells) generated by a method known in
10 the art, and thawed and preferably expanded prior to administration.

[0107] In certain embodiments, the step of generating the population of allogeneic T cells *in vitro* comprises sensitizing (i.e., stimulating) allogeneic T cells to one or more EBV antigens so as to produce EBV-specific T cells. The allogeneic T cells that are used for generating the
15 population of allogeneic T cells *in vitro* can be isolated from the donor of the allogeneic T cells by any method known in the art. In a specific embodiment, the allogeneic T cells are enriched from peripheral blood lymphocytes separated from PBMCs of the donor of the allogeneic T cells.

[0108] In particular embodiments, the step of sensitizing
20 allogeneic T cells loading or transforming an antigen presenting cell, such as dendritic cells, cytokine-activated monocytes, or peripheral blood mononuclear cells with at least one immunogenic peptide derived from one or more EBV antigens. To this end, the antigen presenting cell can be loaded or transformed with, for example, a pool of or a polytope comprising
25 overlapping peptides derived from one or more EBV antigens. In one specific embodiment, the step of generating the population of allogeneic T cells *in vitro* comprises sensitizing allogeneic T cells using peripheral blood mononuclear cells.

[0109] Suitably, the aforementioned method includes the further
30 step of administering a therapeutic agent to the subject. Similarly, the above composition may further include a therapeutic agent. As used herein, the term "*therapeutic agent*" refers to a compound or molecule used to image, affect, treat, address, prevent or ameliorate an undesirable

condition or disease, such as an EBV-associated disease, disorder or condition in a subject.

[0110] The therapeutic agent may be any as are known in the art. In some embodiments, the therapeutic agent is or comprises an anti-cancer treatment or an anti-cancer agent. Generally, drugs, biomolecules (e.g., antibodies, inhibitory nucleic acids such as siRNA) or chemotherapeutic agents are referred to herein as "*anti-cancer therapeutic agents*". By way of example only, these may include: chemotherapeutic agents such as paclitaxel, doxorubicin, methotrexate, irinotecan, dacarbazine, temozolomide and cisplatin, although without limitation thereto; biotherapeutic or immunotherapeutic agents, such as anti-PD-1 antibodies (e.g., Nivolumab) and anti-CTLA4 antibodies (e.g., Ipilimumab), although without limitation thereto; and/or molecularly targeted agents such as MAPK pathway (i.e., Ras-Raf-MEK-ERK signalling) inhibitors and BET inhibitors.

[0111] In particular embodiments, the therapeutic agent is selected from the group consisting of an immunotherapeutic agent, a mitogen-activated protein kinase (MAPK) pathway inhibitor, a BET inhibitor and any combination thereof.

[0112] The term "*immunotherapeutic agent*" as used herein, refers to any agent that can induce, enhance, or suppress an immune response in a subject. In certain embodiments, an immunotherapeutic agent can be an immune checkpoint modulator. As used herein, the term "*immune checkpoint modulator*" refers to a molecule that can completely or partially reduce, inhibit, interfere with, or modulate one or more immune checkpoint proteins that regulate T-cell activation or function. In certain embodiments, the immune checkpoint modulator is an immune checkpoint inhibitor.

[0113] Non-limiting examples of immune checkpoint proteins include cytotoxic T-lymphocyte-associated antigen (CTLA; e.g., CTLA4) and its ligands CD 80 and CD86; programmed cell death protein (PD, e.g., PD-1) and its ligands and PDL2; indoleamine-pyrrole 2,3-dioxygenase-1 (IDO1); T cell membrane protein (TIM, e.g., TIM3); adenosine A2a receptor (A2aR); lymphocyte activation gene (LAG, e.g., LAG3); killer immunoglobulin receptor (KIR); CD96; and the like. It will be appreciated

that these proteins are typically responsible for co-stimulatory or inhibitory T-cell responses. Immune checkpoint proteins can broadly regulate and maintain self-tolerance and the duration and amplitude of physiological immune responses.

5 **[0114]** In certain embodiments, an immune checkpoint modulator (e.g., an immune checkpoint inhibitor) can be a small molecule, an antibody, a recombinant binding protein, or a peptide that binds to or inhibits a biological activity of an immune checkpoint protein.

10 **[0115]** Non-limiting examples of immune checkpoint modulators (e.g., immune checkpoint inhibitors) include CTLA4 inhibitors (e.g., Ipilimumab), PD1 inhibitors (e.g., nivolumab), PDL1 inhibitors (e.g., Atezolizumab, Avelumab, Durvalumab), LAG3 inhibitors, KIR inhibitors, B7-H3 ligands, B7-H4 ligands, CD96 inhibitors and TIM3 inhibitors. In particular
15 embodiments, the immune checkpoint inhibitor is selected from the group consisting of an anti-PD1 antibody, an anti-PDL1 antibody, an anti-CTLA4 antibody, an anti-LAG3 antibody, an anti-TIM3 antibody, an anti-CD96 antibody and any combination thereof.

20 **[0116]** In one particular embodiment, the immune checkpoint inhibitor is or comprises a PD1 inhibitor, and more particularly an anti-PD1 antibody. Exemplary PD1 inhibitors and anti-PD1 antibodies include Pembrolizumab, Nivolumab, Cemiplimab, Spartalizumab, Camrelizumab, Sintilimab, Tislelizumab, Toripalimab, AMP-224 and AMP-514.

25 **[0117]** As used herein, an "*antibody*" is or comprises an immunoglobulin protein, inclusive of fragments thereof. The term "*immunoglobulin*" includes any antigen-binding protein product of a mammalian immunoglobulin gene complex, including immunoglobulin isotypes IgA, IgD, IgM, IgG and IgE and antigen-binding fragments thereof. Included in the term "*immunoglobulin*" are immunoglobulins that are recombinant, chimeric or humanized or otherwise comprise altered or
30 variant amino acid residues, sequences and/or glycosylation, whether naturally occurring or produced by human intervention (e.g., by recombinant DNA technology).

[0118] The invention also includes within its scope antibody fragments, such as Fc, Fab or F(ab)2 fragments or single chain Fv antibodies

(scFvs). The invention is also contemplated to include multivalent recombinant antibody fragments, so-called diabodies, triabodies and/or tetrabodies, comprising a plurality of scFvs, as well as dimerisation-activated demibodies (*e.g.*, WO/2007/062466). By way of example, such antibodies may be prepared in accordance with the methods described in Holliger *et al.*, 1993 *Proc Natl Acad Sci USA* 90:6444-6448; or in Kipriyanov, 2009 *Methods Mol Biol* 562:177-93 and herein incorporated by reference in their entirety.

[0119] Generally, antibodies and antibody fragments may be polyclonal or monoclonal. It will also be appreciated that antibodies may be produced as recombinant synthetic antibodies or antibody fragments by expressing a nucleic acid encoding the antibody or antibody fragment in an appropriate host cell. Non-limiting examples of recombinant antibody expression and selection techniques, inclusive of phage display methods, are provided in Chapter 17 of Coligan *et al.*, *CURRENT PROTOCOLS IN IMMUNOLOGY* and Zuberbuhler *et al.*, 2009, *Protein Engineering, Design & Selection* 22 169.

[0120] As used herein, the term "MAPK inhibitor" refers to any compound or chemical entity that, upon administration to a subject, results in inhibition the MAPK pathway in one or more cells, such as cancer cells, of the subject. MAPK inhibitors include but are not limited to low molecular weight inhibitors, antibodies or antibody fragments, antisense constructs, small inhibitory RNAs (*i.e.* RNA interference by dsRNA; RNAi), and ribozymes. In some embodiments, the MAPK inhibitor is a small organic molecule. MAPK inhibitors include, for example, RAS inhibitors, RAF inhibitors, MEK inhibitors, ERK inhibitors, JNK inhibitors and/or p38 inhibitors.

[0121] The MAPK pathway inhibitor may be any as are known in the art, inclusive of specific inhibitors of Ras (*i.e.*, HRas, KRas and/or NRas), Raf (*i.e.*, A-Raf, B-Raf and/or C-Raf), mitogen-activated protein kinase kinase (*i.e.*, MEK1/2) and/or extracellular signal-regulated kinase (*i.e.*, ERK1/2) function and/or signalling, inclusive of mutant variants thereof. By way of example, such MAPK pathway inhibitors may be chosen from among:

[0122] i) MEK inhibitors: AZD6244, R04987655, R05126766, TAK-733, MSC1936369B (AS703026), GSK1 120212, BAY86-9766, GDC-0973, GDC-0623, PD325901, ARRY-438162, CM 040, E6201, ARRY300;

[0123] ii) Raf and/or BRaf selective inhibitors: PLX4032, GSK21
5 18436, Sorafenib (BAY-43-9006), BMS-908662 (XL-281), RAF265, RG-7256 (R05212054, PLX3603), R05126766, ARQ-736, E-3810, DCC-2036;

[0124] iii) ERK inhibitors: Ulixertinib (BVD-523), SCH772984, DEL-22379, MK-8353 (SCH900353), AZD0364, VX-11e, CC-90003;

[0125] iv) Ras inhibitors: MCI-062, Salirasib, BAY 293, ARS-1620.

10 **[0126]** It is envisaged that the BET inhibitor may be any as is known in the art. As used herein, the term "*BET inhibitor*" refers to a compound that binds to BET and inhibits and/or reduces a biological activity of BET. In some embodiments, the BET inhibitor substantially or completely inhibits a biological activity of BET. In some embodiments, the biological
15 activity is binding of BET to chromatin (e.g., histones associated with DNA) and/or another acetylated protein. Suitably, the BET inhibitor inhibits one or more of BRD2, BRD3, BRD4, and BRDT. BET inhibitors include modulators of bromodomain-containing proteins such as the benzimidazole derivatives disclosed in U.S. Pub. No.: 2014/0336190. Exemplary BET inhibitors include
20 I-BET 151 (GSK1210151A), I-BET 762 (GSK525762), OTX-015, TEN-010, CPI-203, CPI-0610, olinone, RVX-208, LY294002, AZD5153, MT-1 and MS645.

[0127] In another aspect, the invention relates to a method of treating or preventing an EBV-associated disease, disorder or condition in a
25 subject, said method including the steps of:

[0128] (a) administering to the subject a population of allogeneic T cells that bind or recognize an epitope of an EBV antigen; and

[0129] (b) administering to the subject a therapeutic agent, wherein the therapeutic agent is selected from the group consisting of an
30 immunotherapeutic agent, a MAPK pathway inhibitor, a BET inhibitor and any combination thereof;

[0130] to thereby treat or prevent the EBV-associated disease, disorder or condition in the subject.

[0131] In a related aspect, the invention resides in a pharmaceutical composition for treating or preventing an EBV-associated
5 disease, disorder or condition in a subject, the composition comprising:

[0132] a population of allogeneic T cells that bind or recognize an epitope of an EBV antigen;

[0133] a therapeutic agent, wherein the therapeutic agent is selected from the group consisting of an immunotherapeutic agent, a MAPK
10 pathway inhibitor, a BET inhibitor and any combination thereof; and

[0134] optionally a pharmaceutically acceptable carrier, diluent and/or excipient.

[0135] By "pharmaceutically acceptable carrier" is meant a pharmaceutical vehicle comprised of a material that is not biologically or
15 otherwise undesirable, i.e., the material may be administered to a subject along with the selected active agent without causing any or a substantial adverse reaction. Carriers may include excipients and other additives such as diluents, detergents, coloring agents, wetting or emulsifying agents, pH buffering agents, preservatives, transfection agents and the like.

20 **[0136]** Similarly, a "pharmacologically acceptable" salt, ester, amide, prodrug or derivative of a compound as provided herein is a salt, ester, amide, prodrug or derivative that this not biologically or otherwise undesirable.

[0137] The statements which follow apply equally to the two
25 aforementioned aspects.

[0138] Suitably, the population of allogeneic T cells and cells of the EBV-associated disease, disorder or condition share a human leukocyte antigen (HLA) allele that encodes a MHC protein. In particular embodiments, the MHC protein presents the epitope of the EBV antigen on cells of the
30 EBV-associated disease, disorder or condition.

[0139] The immunotherapeutic agent, the MAPK pathway inhibitor and/or the BET inhibitor can be any as are known in the art, such as those hereinbefore described. In particular embodiments, the MAPK pathway inhibitor is or comprises a MEK1/2 inhibitor. In another embodiment, the
5 immunotherapeutic agent is or comprises an immune checkpoint inhibitor, such as an anti-PD1 antibody.

[0140] Suitably, the population of allogeneic T cells is administered prior to, simultaneously with and/or subsequent to administration of the therapeutic agent. Accordingly, in certain embodiments, the subject is
10 administered the therapeutic agent and subsequently administered the allogeneic T cells. In alternative embodiments, the individual is administered the allogeneic T cells and subsequently administered the therapeutic agent. In a further alternative embodiment, the allogeneic T cells are administered simultaneously with the therapeutic agent.

[0141] In one embodiment, the method of the present aspect further includes the initial step of generating the population of allogeneic T cells *in vitro*, such as by those methods hereinbefore described.

[0142] Suitably, the EBV antigen and/or the further EBV antigen is selected from the group consisting of EBNA1, EBNA2, EBNA3A, EBNA3B,
20 EBNA3C, LMP1, LMP2 and any combination thereof. More particularly, the EBV antigen and/or the further EBV antigen suitably is or comprises EBNA1, LMP1 and/or LMP2.

[0143] Suitably, the EBV-associated disease, disorder or condition is or comprises an EBV-associated cancer, such as those hereinbefore
25 described. In one embodiment, the EBV-associated cancer is selected from the group consisting of nasopharyngeal carcinoma, NKT cell lymphoma, Hodgkin's Lymphoma, post-transplant lymphoproliferative disease, Burkitt's lymphoma, Diffuse large B-cell lymphoma, gastric cancer, and any combination thereof.

[0144] In still another aspect, the invention relates to use of a first
30 population of allogeneic T cells, such as those described herein, that bind or recognize a first epitope of an EBV antigen in the manufacture of a medicament for the treatment or prevention of an EBV-associated disease, disorder or condition in a subject; wherein the first population of allogeneic

T cells is to be administered in combination with: (a) a second population of allogeneic T cells, such as those described herein, that bind or recognize a second epitope of the EBV antigen or a further EBV antigen; and/or (b) a therapeutic agent, such as that described herein, wherein the therapeutic agent is selected from the group consisting of an immunotherapeutic agent, a MAPK pathway inhibitor, a BET inhibitor and any combination thereof.

[0145] In a final aspect, the invention provides a first population of allogeneic T cells, such as those described herein, that bind or recognize a first epitope of an EBV antigen for use in the treatment or prevention of an EBV-associated disease, disorder or condition in a subject; wherein the first population of allogeneic T cells is to be administered in combination with: (a) a second population of allogeneic T cells, such as those described herein, that bind or recognize a second epitope of the EBV antigen or a further EBV antigen; and/or (b) a therapeutic agent, such as that described herein, wherein the therapeutic agent is selected from the group consisting of an immunotherapeutic agent, a MAPK pathway inhibitor, a BET inhibitor and any combination thereof.

[0146] With respect to the aforementioned aspects, the term "subject" includes but is not limited to mammals inclusive of humans, performance animals (such as horses, camels, greyhounds), livestock (such as cows, sheep, horses) and companion animals (such as cats and dogs). In one particular embodiment, the subject is a human.

[0147] So that preferred embodiments may be described in detail and put into practical effect, reference is made to the following non-limiting Examples.

EXAMPLES

Example 1

[0148] Allogeneic "off-the-shelf" T cell therapy has emerged as a powerful tool to treat infectious complications in transplant recipients. These allogeneic antigen-specific T cells are expanded from peripheral blood lymphocytes collected from a large panel of healthy donors provides diverse HLA coverage and can be cryopreserved and administered in HLA-matched transplant patients in need. In this Example, we provide the preclinical

assessment of allogeneic EBV-specific T cells as a therapeutic tool for the treatment of multiple cancers. Furthermore, we have also demonstrated that a combination of allogeneic antigen-specific T cells and antibodies blocking the PD1/PD-L1 axis significantly improved the efficacy of adoptive
5 T cell therapy against EBV cancers.

Materials & Methods

Cell culture

[0149] The EBV-associated cell lines used in this study were purchased from the American Type Culture Collection (ATCC, Manassas,
10 Virginia, USA) and were cultured and maintained as per ATCC recommendations. The respective EBV-associated cell lines used in the study and their respective HLA is listed in Table 1. The cultures of these cell lines were maintained by incubating at 37°C with 20% oxygen levels and 5% CO₂. All tissue culture plasticwares was purchased from Corning® Stone
15 Staffordshire, UK (flasks and plates) and Costar® Washington DC, USA (plastic pipettes). All the cell lines were regularly tested for Mycoplasma infection and authenticated using short tandem repeat (STR) profiling by scientific services at QIMR Berghofer Medical Research Institute.

RNA extraction and Quantitative real-time PCR

20 [0150] RNA was extracted either from respective cell lines using the QIAgen RNeasy® kit (Valencia, CA, USA) as per manufacturer's directives. 1×10^6 cells of respective cell lines were plated and harvested using trypsin-EDTA (Sigma Aldrich®) and washed (PBS, 2 times) after which appropriate volume of RLT buffer at 4°C (supplied in the kit) was
25 added and following steps as indicated by manufacturer was performed. A DNase digestion step was performed using the DNase enzyme provided in the iScript™ cDNA kit (Bio-Rad Laboratories Inc) after RNA extraction. The RNA quality and quantity was accessed using Nanodrop ND-1000 spectrophotometer (Thermo-Scientific). Reverse transcription was
30 performed using iScript™ Reverse Transcriptase (Bio-Rad Laboratories Inc.) as per manufacturer instruction. The cycle condition used was: Priming at 25°C for 5 minutes, reverse transcription at 46°C for 20 minutes and reverse transcriptase inactivation at 95°C for 1 minute. qRT-PCR was performed in 384 well plate using Biorad CFX384 Touch™ Real-Time PCR

Detection System. The primers comprised of EBV-associated genes LMP1, LMP2 and EBNA1 that were obtained from the respective publications. The composition of the mastermix in an overall volume of 10 μ L include: 5 μ L of Sybr green, 1 mM of each primers, 1 μ L of diluted cDNA and 3 μ L of H₂O for three biological replicates performed in duplicates. The cycle condition used was: 95°C for 5 minutes, followed by 40 cycles of the following: 95°C for 10 seconds, 60°C for 10 seconds and 72°C for 5 seconds, and a final elongation step of 72°C for 5 minutes. Calculations of C_t value was performed using the accompanying Biorad CFX384 software, version 1.5.0.39 following which the calculations were performed using the $\Delta\Delta C_t$ method, with values normalized to 18sRNA and HPRT. For each biological cDNA sample analysis, a negative control containing cDNA solution without treating with reverse transcriptase to ensure no genomic DNA contamination. Alongside, a regular negative control containing only H₂O was included for each primer set. The primers comprised of LMP1: FP- 5'-CAGTCAGGCAAGCCTATGA3', RP-5'-CTGGTTCCGGTGGAGATGA3'; LMP2: 5'-AGCTGTAAGTGTGGTTTCCATGAC-3', RP-5'-GCCCCCTGGCGAAGAG-3'; EBNA1: FP-5'-TACAGGACCTGGAAATGGCC-3', RP-5'-TCTTTGAGGTCCACTGCCG-3'; HPRT1: FP- 5'-CCTGGCGTCGTGATTAGTGAT-3', RP-5'-AGACGTTTCAGTCCTGTCCATAA-3'; 18sRNA: 5'-CGAAAGCATTACCAAGGAC-3', RP-5'-TTATTGTGTCTGGACCTGG-3'.

Generation of T cells

[0151] To generate LMP/EBNA1-specific "off the shelf" T-cell bank, peripheral blood mononuclear cells (PBMCs) were harvested from 100–300 mL of venous blood of seropositive donors covering a wide HLA spectrum. The AdE1-LMPpoly vector which comprised of a polyepitope of 16 HLA-restricted LMP1&2 epitopes fused to a truncated gly/ala deleted EBNA1 gene [11, 12], was then used to infect 30% of the PBMCs (MOI of 10:1). These transfected PBMCs were then irradiated and co-cultured with the remaining PBMCs for two weeks. Cultures were supplemented with fresh growth medium and 120 IU/mL of recombinant IL-2 every 3–4 days (Komtur Pharmaceuticals). Expanded T-cells were tested for antigen specificity and microbial contamination prior to release for infusion. The respective T cells used to target the HLA-matched EBV-associated cancer cell lines are listed in Table 1.

Intracellular Cytokine Assay

[0152] To analyse the frequency of LMP1&2- and EBNA1-specificity in the AdE1-LMPpoly vector transfected T-cells products, they were stimulated for 4 hours in the presence of GolgiPlug (BD Biosciences) with a pool of defined epitopes from LMP1&2 or EBNA1 or with an overlapping set of peptides encompassing the whole EBNA1 protein (all from Mimotopes, GenScript or JPT Technologies). For multiparametric analysis, cells were stimulated for 4 hours in the presence of GolgiPlug and GolgiStop (BD Biosciences) with the peptides listed above and anti-CD107a-FITC (BD Biosciences). Cells were then washed and stained with anti-CD8-PerCPCy5.5 (eBioscience) and anti-CD4-PECy7 (BD Biosciences), fixed and permeabilised with Cytofix/Cytoperm (BD Biosciences), washed again and stained with anti-IFN- γ -AF700 (all from BD Biosciences) [11]. After a further wash, cells were resuspended in PBS and acquired using a BD LSR Fortessa with FACSDiva software (BD Biosciences). Post-acquisition and Boolean analysis was performed using FlowJo software (TreeStar).

Cell Viability Assay

[0153] Cell viability assay was performed using the CellTiter 96® AQueous one cell viability assay reagent (Promega, WI, USA) for three biological replicates per EBV-associated cancer cell lines in triplicate. Briefly, the cancer cells (target cells) were plated at a density of 5000 cells per well in an overall media volume of 200 μ L on a 96-well tissue-culture plate (BD Falcon™). The effector AdE1-LMPpoly transfected T cells were freshly thawed in RPMI-1640 with 10% FCS and 120 IU/mL of recombinant IL-2 at 37°C and 50% CO₂. Post 24 hrs of plating and incubation at 37°C and 50% CO₂, the effector T cells were mixed to the target cells at a gradient ratio of effector to target (E:T) of 5:1-100:1. The exact number of T cells (T₀) used per E:T ratio (E_T) was independently used as control alongside PBS treated target cells (E_s) and sole media (M₀). After 24 hrs of incubation at 37°C and 50% CO₂, MTS was added to each well (1:100 dilution in media) and was incubated for 1 hour following which the plate was centrifuged at 1,200 x g at room temperature for 5 min and absorbance of the mixture at an optical density of 490 nm was measured via a microplate reader. The relative cell viability was calculated using the following formula:

$$\text{Relative cell viability} = \frac{(E_T - M_0) - (T_0 - M_0)}{(E_T - M_0) - (T_0 - M_0)}$$

$$(E_s - M_0)$$

Cell Cytotoxicity Assay

[0154] Cell cytotoxicity assay was performed using the CytoTox 96® Nonradioactive Cytotoxic Assay Kit (Promega, WI, USA) for three biological replicates per EBV-associated cancer cell lines in triplicate [14]. Briefly, the cancer cells (target cells) were plated at a density of 5000 cells per well in an overall media volume of 200 µL on a 96-well tissue-culture plate and similar condition to that of cell viability assay was maintained as described previously. Alongside, we also seeded exact number of target cells (E_M). Following 24 hrs of mixing the effector and target cells at 37°C, 10X lysis agent was added to the E_M well and incubated at 37°C and 50% CO₂ for 45 min. Following complete lysis of target cells, the plate was centrifuged at 1,200 x g at room temperature for 5 min, and the 50 µl supernatant of each well was transferred to another plate. Assay buffer was mixed with substrate mix and aliquoted to each well. Following termination with stop solution, the absorbance of the mixture at an optical density of 490 nm was measured via a microplate reader. The relative lysis in experimental and control well was calculated as follows:

$$\text{Relative cytotoxicity} = \frac{(E_T - M_0) - (T_0 - M_0)}{(E_T - M_0) - (E_s - M_0)}$$

Polychromatic profiling of cancer-cell phenotype

[0155] The respected EBV-associated cancer cells were plated at a density of 1×10^5 cells per well and after 24 hours, were mixed with T cells with an effector to target (E:T) of 50:1 and incubated for 24 hr 37°C and 50% CO₂. For assessing the impact of T cells on cancer cells, cells were then incubated at 4°C with the following antibody: human anti-CD45-V500, anti-CD3-AF700, anti-Ki67-BV421, anti-BCL2-FITC and anti-Active Caspase 3-BV605. Cells were acquired using a BD LSR Fortessa with FACSDiva software (BD Biosciences) and post-acquisition analysis was performed using FlowJo software (TreeStar).

Polychromatic profiling of AdE1-LMPpoly transfected T-cell phenotype

[0156] The effector AdE1-LMPpoly transfected T cells were freshly thawed and were mixed to the target cells (1×10^5) at an effector to target (E:T) of 50:1 and incubated for 24 hr 37°C and 50% CO₂. For assessment of surface phenotype, cells were then incubated at 4°C with the following antibody panels: (i) human anti-CD45-V500, anti-CD3-AF700, anti-CD4-PECy7 and anti-CD8-PerCPCy5.5; (ii) human anti-CD45-V450, anti-CD4-AF700, anti-CD8-PerCPCy5.5, anti-CD14-eFluor450, anti-CD19-eFluor450; anti-PD-1-BV786; (iii) MHC- Class I antibody (clone W6/32) (home made, raised in mouse), LIVE/DEAD Fixable Near-IR Dead Cell Stain (Thermo Fisher Scientific, MA). For intracellular analysis, cells were treated with TF Fixation/Permeabilization buffer (BD Biosciences) and then stained in the presence Perm/Wash with the following antibodies: (i) anti-perforin-BV421, anti-granzyme B-AF700 and anti-granzyme K-FITC. Cells were acquired using a BD LSR Fortessa with FACSDiva software (BD Biosciences) and post-acquisition analysis was performed using FlowJo software (TreeStar).

Animal housing

[0157] All animal work was approved by the QIMR Berghofer Medical Research Institute, Animal Ethics Committee (number A0707-606M) and was performed in strict accordance with the Australian code for the care and use of animals for scientific purposes. All experimental animals were maintained on a mixed (129SV/E X C57BL/6) strain and were housed at the Queensland Institute of Medical Research Animal Facility in OptiMICE® caging (Centennial, Colorado, USA) on a 12-hour light-dark cycle at 25°C. Dried granule food was sterilized by radiation irradiation. The mice had free access to the food and sterile water.

In vivo assessment of therapeutic efficacy of allogeneic EBV-specific T-cells

[0158] A total of 12-24 female NOD/SCID mice (depending on the experiment) of 7–8 weeks old were used in this study. The mice were subjected to irradiation with 0.8 Gy cobalt-60 and after 4 hours, were subcutaneously injected with 5×10^6 cells of respective EBV-associated cancer cells with a 29-gauge needle. The mice were monitored for tumour growth, weight and body score thrice weekly. Once the tumour was palpable, the mice were randomised into respective groups and were treated with respective dosage of PBS or 20×10^6 tumour HLA matched

allogenic EBV-specific T-cells. The tumour size in these mice were measured thrice weekly using the Vernier Calipers. To calculate tumour area the following formula was used: tumour area = B*S where B = largest tumour measurement and S = the smallest, based on two-dimensional caliper measurements as previously described [13].

In vivo assessment of therapeutic efficacy of allogeneic EBV-specific T-cells in humanized mice model

[0159] Fresh human CD34⁺ cord blood cells were obtained from healthy full-term newborns after written parental consent and were enriched using immunomagnetic beads according to the manufacturer's instructions (CD34⁺ selection kit, Miltenyi Biotec, Bergisch-Gladbach, Germany). Female NRG mice of 7–8 weeks old were irradiated twice with 275 cGy at 3-4 hours apart following which they were intravenously injected with 5×10^4 CD34⁺ cells (HLA matched to AdE1-LMPpoly transfected T-cells used for treatment) per mouse with a 29-gauge needle. The mice were monitored twice weekly for body weight, body score and adverse reactions including graft versus host disease (GVHD). In addition, tail vein bleeds were performed at weeks 4, 8, 10 and 12 during which 100 μ L to 200 μ L of blood was collected into EDTA tubes from each mouse at a time to monitor the reconstitution of the human immune system. To assess the reconstitution from the human CD34⁺ cord blood cells, the surface phenotyping was performed using human anti-CD45-V500, mouse anti-CD45-V450, anti-CD3-APC, anti-CD4-AF700, anti-CD8-PerCPCy5.5, anti-CD8-PerCPCy5.5, anti-CD14-FITC, anti-CD19-PeCy5, anti-CD23-BV786, and anti-CD56-BV650. At the 12th week of reconstitution, the humanised NRG mice were intravenously injected with EBV B95-8 at a dose of 10^6 EBV particles in 100 μ L PBS under non-anaesthetic conditions using a 29-gauge needle. At 13th day post EBV infection, the mice were treated with respective dosage of PBS or 20×10^6 tumour HLA matched or switched AdE1-LMPpoly transfected T-cells. The HLA of the respective cord blood cells and the corresponding T cells used to treat the lymphoid malignancies are listed in Table 1. The mice were monitored for 14 days post T cells treatment following which were culled and their spleens were analysed tumour burden.

Immunohistochemistry

[0160] For histologic examination tissues were collected and fixed in 4% formaldehyde in PBS after washing (PBS, 3 times) and was stored in 70% ethanol prior to processing. The tissues were then embedded in paraffin blocks, and 5- μ m-thick sections prepared for staining. Tissues were embedded in paraffin and 4 μ m sections mounted onto Superfrost plus slides using the Sakura Tissue-Tek® TEC™ (Sakura Finetek, Tokyo, Japan). Immunohistochemistry was performed in assistance with the QIMR Berghofer Medical Research Institute in-build facility. Antigen retrieval was performed using 2.94 g tri-sodium citrate in 1 L MQ (pH 6.0) buffer and microwaved. Tissue sections were permeabilized in 0.2% Triton X-100/PBS for 5 min, followed by 0.05% Triton X-100/PBS for 10 min. Tissue sections were treated with 3% (vol/vol) H₂O₂ before immunostaining using the anti-CD3 (1:40 Dako M7254) antibody in 2% BSA followed by secondary antibody (VEMP7402) Dako EnVision™ (Agilent, system Waukesha, WI, USA) and counterstaining with haematoxylin. The slides were scanned on the Aperio® Scanscope® XT (Aperio®, Vista, USA) using 20X or 40X objecting.

Gene Signature Profile using NanoString and infiltrate profiling

[0161] A total of 6 female NOD/SCID mice of 8 weeks old were irradiated with 0.8 Gy cobalt-60 and after 4 hours, were subcutaneously injected with 5×10^6 cells of SNU719 with a 29-gauge needle. Once the tumour size reached 40 mm², the mice were treated with 20×10^6 TI_001 T cells. After 5 days, the tumours were harvested and using FACS, the T cells sorted for viable CD8⁺ population using human anti-CD45-V500, mouse anti-CD45-V450, anti-CD3-APC, anti-CD4-PE and anti-CD8-PerCPCy5.5. RNA was isolated from the sorted viable CD8⁺ population of individual mice using a Qiagen RNeasy kit as described above. Gene expression analysis was performed using the customized 326-NanoString Immune gene expression panel. 50 ng of total RNA per mice sample was used in a final volume of 5 μ l and was mixed with a 3' biotinylated capture probe alongside a 5' reporter probe tagged with a fluorescent barcode from the custom gene expression code set. Probes and target transcripts were hybridized at 65°C for 12-16 h. Hybridized samples were run on the NanoString nCounter preparation station using the recommended manufacturer protocol, in which excess capture and reporter probes were removed and transcript-specific ternary complexes were immobilized on a

streptavidin-coated cartridge. The samples were scanned at maximum scan resolution on the nCounter Digital Analyzer. Data were processed using nSolver Analysis Software and the nCounter Advanced Analysis module. For gene expression analysis data were normalized using the geometric mean of housekeeping genes selected by the GeNorm algorithm.

Statistical analysis

[0162] Student's t-test or one-way or two-way ANOVA with Bonferoni *post hoc* or Mann-Whitney *U* test testing (specified in figure legend) was performed using GRAPHPAD PRISM v6.0 (GraphPAD Software, LaJolla, CA, USA) and the p-values were calculated as indicated in figure legends. Asterisks indicate significant difference (*p < 0.05, **p < 0.01, ***p<0.001 and ****p<0.0001), ns= not significant.

Results

In vitro recognition of multiple cancers by allogenic "off-the-shelf" EBV specific T-cells

[0163] To assess the expression of EBV-encoded genes (LMP1, LMP2 and EBNA1) in multiple EBV-associated malignancies including NPC, gastric cancer, NKT lymphoma and BLCLs, we employed qRT-PCR and analyzed the transcript levels for each of these genes. We observed that in all EBV-associated malignancies, LMP2 and EBNA1 was consistently expressed at higher level when compared to LMP1 (Fig. 1A). We assessed susceptibility of these EBV-positive cancer cells to allogenic "off-the-shelf" EBV-specific T cells specific for LMP1, LMP2 and/or EBNA1 (Fig. 1B; Table 2). Data presented in Figure 1C-D shows that gastric cancer (SNU719), NPC (C17 and C661) and NKT lymphoma (SNKT16) cells were efficiently recognized by allogenic HLA matched EBV-specific T cells at varying effector to target ratios. Furthermore, Annexin V binding assay also showed increase in Annexin V binding capacity indicating target cell death in comparison to the mock-treated control (Fig. 1D-E).

[0164] In the next set of experiments, we analysed the impact of the allogenic EBV-specific T cells on the phenotypic changes in EBV-associated cancer cells. We observed significant reduction (p<0.001) in proliferation rate of both gastric cancer, SNU719 and NPC, C17 cells, after 24 hrs in presence of HLA matched allogenic EBV-specific T cells as shown

by Ki67staining (Fig. 2A). Furthermore, we also observed a significant increase ($p<0.001$) of active Caspase 3 staining in addition to significant reduction ($p<0.01$) in BCL2 staining suggesting increased cell death induced by the EBV-specific T cells (Fig. 2A). We also investigated the impact of EBV-associated cancer cells on allogeneic EBV-specific T-cells. We observed a significant increase ($p<0.01$) in CD8⁺ T cell population in presence of EBV-associated cancer cells (Fig. 2B). Consistent with this data, we observed a significant increase in Ki67 expression on CD8⁺ T cells, when exposed to EBV-positive cancer cells (Fig. 2B). Furthermore, these T cells also showed a high level of effector function as indicated by significantly increased expression of GzmB, GzmK and Perf staining (Fig. 2B). Collectively, these data demonstrate that the allogeneic EBV-specific T cells can efficiently recognize HLA-matched multiple types of EBV-associated cancer cells *in vitro*.

Assessment of therapeutic efficacy of allogeneic EBV-specific cytotoxic T cells *in vivo*

[0165] Having established efficient recognition of multiple EBV-associated cancers by allogeneic EBV-specific T cells *in vitro*, we next assessed therapeutic efficacy of these effector cells *in vivo*. In the first set of experiments immuno-deficient NOD-SCID mice were inoculated with EBV-associated NPC tumours, C17 and C666.1 (subcutaneously) after irradiation. These animals were treated with HLA matched allogeneic EBV-specific T cells when tumours of each animal reached 25 mm². These animals were treated with either a single or two infusions (2×10^7 T cells for each infusion/animal) of allogeneic HLA matched EBV-specific T cells and monitored for tumour outgrowth. Data presented in Figure 3 shows that a single infusion of allogeneic HLA A2/B40-restricted or HLA A11/B58-restricted LMP2-specific T cells (2×10^7 T cells) were sufficient to significantly reduce the tumour outgrowth and also improved overall survival of tumour-bearing mice (Fig. 3A & B). A further improvement in tumour burden and overall survival was observed when these animals were treated with two infusions of allogeneic EBV-specific T cells (Fig. 3C &D).

[0166] In the next set of experiments, we extended the therapeutic efficacy analysis to gastric cancer. In these experiments, immuno-deficient NOD-SCID mice were inoculated with EBV-associated gastric cancer,

SNU719 and treated with HLA A24-restricted allogenic LMP2-specific T cells when tumours of each animal reached 25 mm². Consistent with the data obtained with NPC tumour model, a significant reduction in tumour burden and improved overall survival was observed when these animals were
5 treated with HLA matched allogenic LMP2-specific T cells (Fig. 4A). Interestingly, we noticed that while the tumour outgrowth was significantly reduced after first T cell infusion, this therapeutic benefit was less pronounced after second T cell infusion. A possible explanation for this phenomenon could be due to presence of immunosuppressive tumour
10 microenvironment [16, 17] or HLA-loss leading immune escape [18], leading to adversely impact clinical outcome. Thus, we hypothesized that the EBV-associated tumours override the therapeutic impact of allogenic EBV-specific T-cells by altering their HLA-expression or modulating EBV gene expression which might hamper the presentation of EBV epitopes to
15 the CD8⁺ T cells. To explore this hypothesis, we established three groups of mice bearing gastric cancer (SNU719) and treated one group of mice (G1) using three continuous dosage of the same HLA-matched allogenic EBV-specific T cells (HLA A24-restricted LMP2-specific T cells). Simultaneously, we also treated another group (G2) with two continuous
20 dosage of the same HLA-A24-restricted allogenic EBV-specific T cells but switched the third dose to a different T cell line (HLA B7-restricted, EBNA1-specific) (Fig. 4B). We observed that, in comparison to G1, the G2 group demonstrated a significant reduction in tumour outgrowth and improved overall survival after the infusion of the third dosage of T cells (Fig. 4B).
25 Interestingly, G1 group showed minimal impact on tumour growth after the third infusion and much higher tumour burden when compared to animals in G2 group (Fig. 4B). Collectively, these data clearly demonstrate that allogenic HLA matched T cells can efficiently block tumour outgrowth and improve overall survival of mice bearing EBV-associated epithelial tumours.

30 ***Allogeneic EBV-specific T cells adoptive immunotherapy effectively inhibits outgrowth of EBV-associated lymphoid malignancies***

[0167] As mentioned previously, EBV is etiologically involved with multiple diseases including lymphoproliferative diseases (LPD) in immunocompromised patients such as PTLDs, AIDs- associated lymphomas
35 and other malignant lymphomas namely Hodgkin and Burkitt lymphoma [19-22]. To further demonstrate the potential therapeutic efficacy of

allogenic EBV-specific T-cells, we utilized the humanized mice model harboring the functionally reconstituted human immune system. The reconstitution of human immune system was established using intravenous administration of cord blood derived CD34⁺ stem cells in NOD-Rag1^{null} IL2rg^{null} (referred to as NRG) mice and these animals were regularly monitored as outlined in Fig. 5A & B. After 12 weeks these mice were infected with EBV (QIMR-WIL strain) and following the development of EBV-LPD were adoptively treated with HLA-matched allogenic EBV-specific T cells. Two independent sets of experiments were performed. In the first set, EBV-LPD bearing NRG mice were split into three groups (6 mice in each group) and were either mock treated or infused with T cell therapy (referred to as G1 and G2). Animals in G1 group were treated with three doses of HLA A2 and A24-restricted allogeneic LMP1 and LMP2-specific T cells (2×10^7 T cells/dose), while animals in G2 group were given two doses of HLA A2 and A24-restricted allogeneic LMP1 and LMP2-specific T cells (2×10^7 T cells/dose) and a single dose of HLA A2, B40 and Cw3-restricted LMP1, LMP2 and EBNA1-specific T cells (2×10^7 T cells). Data presented in Figure 5C-D shows that animals in G1 group showed significantly reduced tumour burden when compared mock-treated mice. However, animals in G2 group treated with a combination of two different allogenic EBV-specific T cells showed significantly reduced tumour burden when compared to mock treated and G1 animals. These observations were further confirmed in a second set of independent experiments where animals treated with allogenic EBV-specific T cells also showed significantly lower tumour burden (Fig. 5E-F). These data further demonstrate that allogenic HLA matched EBV-specific T cells can efficiently block tumour outgrowth and improve overall survival of mice bearing EBV-associated lymphoid malignancies.

Blocking PD1/PD-L1 axis augments therapeutic efficacy of allogeneic EBV-specific T cells

[0168] To further delineate the interaction of adoptively transferred allogenic EBV-specific T cells and tumour cells *in vivo*, we isolated infiltrating T cells from the SNU719 tumours and analysed transcriptional signature using NanoString technology. In addition, we also validated expression of some of the checkpoint molecules using specific antibodies. Data presented in Figure 6A shows heat map of gene expression in T cell therapy product and purified tumour infiltrating human T cells. This

analysis showed that a number of cellular genes involved in effector cell function and transcriptional factors associated with effector function were down-regulated in tumour infiltrating human lymphocytes. In contrast, expression of a number of checkpoint molecules were upregulated in these
5 T cells. To validate the expression of these checkpoint molecules, we stained tumour infiltrating human lymphocytes with specific antibodies and compared their expression with T cell therapy administered to tumour-bearing mice. This analysis confirmed the NanoString expression and showed that tumour infiltrating human lymphocytes expressed high levels
10 of PD-1, LAG3 and TIM3 (Fig. 6B).

[0169] Based on these observations, we hypothesized that a combination of checkpoint inhibitor and T cell therapy may offer better therapeutic benefit against EBV-associated tumours. To test our hypothesis whether the upregulated PD1/PD-L1 axis influence the cancer cells in
15 gaining adaptive immune resistance, we blocked PD1 using anti-PD1 antibody (Nivolumab) in combination with the allogenic EBV-specific T cell *in vivo*. Specifically, Nivolumab was administered 24hrs after T cell infusion and we observed that the combination group demonstrated significantly reduced SNU719 gastric cancer outgrowth ($p<0.0001$) in comparison to
20 monotherapy and mock-treated groups (Fig. 6C). In addition, we observed significantly reduced tumour size indicated by the reduced tumour weight observed in the combination group when compared to monotherapy groups (Fig. 6D). Importantly, we observed that the combination group demonstrated significantly improved ($p<0.0001$) survival post therapy in
25 comparison to monotherapy or mock-treated group (Fig 6E). Notably, the combination group showed ~2 fold ($p<0.01$) better survival in comparison to only T cell treated group (Fig. 6E). Collectively, these data highlight the PD1/PD-L1 signalling pathway negatively dictate the fate of the allogenic CD8+ T cells in eliminating the cancer cells as its inhibition enables
30 augmentation of the allogenic EBV-specific CD8+ T cells *in vivo*.

TABLE 1

List of EBV-associated cancer cells and allogeneic EBV-specific T cells used to treat in the study

Cancer cells or cord blood	HLA typing of cancer cells or cord blood	T cells used
SNU719	A*24:02, 24:02; B*07:02,52:01; C*07:02, 12:02	TI_001 and TI_004
C17	A*02:01, 26:01; B*44:02, 51:01; C*05:01, 14:02	TI_002
C666.1	B*58:02; C*03:04	TI_003
SNKT16	A*02:01, 24:02; B*48:01 ,52:01; C*08:03, 12:02	TI_001 and TI_002
CB33A	A*02:01, 03:01; B*40:01, 44:02; C*03:04, 05:01	TI_005 and TI_002
CBO3	A*02:01, 03:01; B*44:02, 58:01; C*05:01, 07:18	TI_001 and TI_003

TABLE 2

HLA and antigen recognition of the respective allogeneic EBV-specific T cells used in the study

Allogenic EBV-specific T cells batch code	HLA typing of T cell donor	EBV antigen specificity (HLA restriction)
TI_001	A*11:01, 24:02; B*40:01, 40:01; C*03:04, 03:04	LMP2 (A*11:01,24:02) and EBNA1(C*03:04)

TI_002	A*02:01, 02:01; B*40:01, 40:01; C*03:04, 03:04	LMP1 (A*02:01); LMP2 (A*02:01, B*40:01); EBNA1 (*03:04)
TI_003	A*11:01, 33:03; B*40:01, 58:01; C*03:02, 03:04	LMP1(58:01); LMP2 (B*40:01,58:01)
TI_004	A*03:01, 03:01; B*07:02, 07:02; C*07:01, 07:02	EBNA1(B*07:02)
TI_005	A*02:01, 23:01; B*41:02, 44:02; C*05:01, 17:01	LMP1 (A*02:01); LMP2 (A*02:01, 23:01)

Example 2

**Efficacy of Dual Combination of MEK1/2 and BET Inhibition with
EBV-Specific T Cells**

5

10 [0170] Targeted therapies, which inhibit molecular or biochemical pathways critical for tumour growth and maintenance, could prove to be of great importance in making an impact on immune contexture of tumours. Of late, multiple studies have demonstrated that targeted therapies might also modulate the immune response, such as attenuating the function of specific immune cell population, namely cytotoxic T lymphocytes and T_{regs} [23]. They influence T cell priming and also dictate their differentiation into memory and effector phenotypes, alongside augmenting antigen tumour presentation by dendritic cells enabling better sensitization of tumour cells to immune-mediated destruction [23]. While, the likely interplay of immunotherapy and targeted therapy remains to be fully elucidated, the synergism and toxicity profile of combination approaches will heavily depend on timing, sequence and dosage [23].

20 [0171] Of particular interest is mitogen-activated protein kinase (MAPK) pathway, which is known to upregulate production of IL-8 and VEGF

which in turn induce inhibitory effects on T cell function and recruitment [24]. Recent studies have indicated that MEK1/2 inhibition selectively blocks naïve but not antigen-experienced effector T-cell activation [25]. In addition, independent studies have shown BRAF inhibitors to have immune-sensitization potential via the up-regulation of tumour antigen expression and presentation; an example can in case of melanoma where in MAPK upregulation results in upregulation of melanocyte differentiation antigens (MADs) [26, 27]. A recent study based on a murine model, demonstrated improved efficacy of pmel-1 ACT and BRAF inhibitor dabrafenib in combination with trametinib (MEK inhibitor), as the triple combination increased T cell infiltration into tumours, improved *in vivo* cytotoxicity and led to complete tumour regression in a syngeneic *BRAF*^{V600E} driven melanoma mouse model [28]. In addition, Kang *et al*, have demonstrated that trametinib enhances MHC class I expression in human HNSCC cell lines in a STT3 dependent manner enabling better CD8+ T cell infiltration [29].

[0172] Independently, epigenetic modification of DNA using small molecule epigenetic modifiers can also alter the immune gene signature and impact antigen processing, presentation and immune evasion [30, 31]. Recently, Kagoya *et al*, have shown that the bromodomain and extra-terminal (BET) motif protein inhibitor, JQ1 maintains the functional properties of stem cell-like and central memory of CD8⁺ T cells [32]. Mechanistically, BRD4 (a BET protein) directly regulates BATF (a transcription factor) expression in CD8⁺ T cells as BATF dictates the differentiation process in T cells into effector memory phenotype. As such, JQ1 treated CD8⁺ T cells showed enhanced anti-tumour effects in murine adaptive T cell model against melanoma [32]. In addition, JQ1 is associated with downregulation of MYC in multiple cancers [33]. MYC, which has been shown to strongly regulate the tumour microenvironment by transcriptionally regulating immune modulators such as PD-L1 and CD47 [34]. Thus, MYC inhibition could strongly result in anti-tumour progression by downregulation of the hostile tumour microenvironment and promote immune-mediated tumour elimination.

Results

Combining MEK1/2 inhibitor with EBV-specific T cells

[0173] We treated SNU719 cells (gastric cancer cells) with MEK1/2 inhibitor (AZD6244 (or selumetinib) and trematinib) at concentration of 0.5 μ M and 1.0 μ M respectively, as individual treatment or in combination with EBV-specific T cells (25:1) as effector to target ratio. We observed that the cell viability of SNU719 was significantly reduced in presence of the combination of MEK1/2 inhibitor and EBV-specific T cells compared the individual treatment (Fig. 7A). Similarly, we observed that the dual combination group resulted in significantly higher binding of Annexin V among the SNU719 cells compared to individually treatment groups (Fig. 7B). In addition, using Xcellegence, we observed that the dual combination resulted in faster cell death among SNU719 cells compared to individual treatment of either MEK1/2 inhibitor or EBV-specific T cells (Fig. 7C). Collectively, these results highlight the efficacy of the dual combination of MEK1/2 inhibition with EBV-specific T cells *in vitro*.

15 **Combining JQ1 inhibitor with EBV-specific T cells**

[0174] We treated SNU719 cells with JQ1 inhibitor at concentration of 5.0 μ M, as individual treatment or in combination with EBV-specific T cells (25:1) as effector to target ratio. We observed that the cell viability of SNU719 was significantly reduced in presence of the combination of JQ1 inhibitor and EBV-specific T cells compared the individual treatment (Fig. 8A). Similarly, we observed that the dual combination group resulted in significantly higher binding of Annexin V among the SNU719 cells compared to individually treatment groups (Fig. 8B). Collectively, these results highlight the efficacy of the dual combination of BET inhibition with EBV-specific T cells *in vitro*.

EXAMPLE 3

[0175] To determine the upregulation of MAPK pathway in EBV-associated solid cancers, we first identified the IC₅₀ value of MEK1/2 inhibitors (AZD6244 or selumetinib and trematinib) across nasopharyngeal and gastric cancer cell lines (with drug concentration ranging from 0.1 μ M-5 μ M). We observed that compared to NPC43^(EBV-) cell line, EBV-associated cell lines uniformly demonstrated high dependency on MAPK pathway as both the inhibitors achieved ~50% reduction in cell viability (IC₅₀) at a

concertation of $\sim 2.5 \mu\text{M}$ using MTS assay (Figure 9). In the next set of experiments, we wanted to determine the impact of MEK1/2 inhibition in combination with allogeneic EBV-specific T cells on EBV-associated solid cancers. As such, we treated the respective EBV-associated cell lines (both
5 gastric and nasopharyngeal) individually or in combination with MEK1/2 inhibitors (both selumetanib and trematinib) and EBV-specific T cells. We chose the sub IC_{50} value (or IC_{25} value) of the respective MEK1/2 inhibitors ($1 \mu\text{M}$) alongside an effector to target ratio of 25:1 of the respective HLA matched allogeneic EBV-specific T cells for the *in vitro* treatment. We
10 observed that the cell viability of the respective nasopharyngeal (C17 and C666.1) and gastric cancer cells (SNU719 and YCCLE1) was significantly reduced in presence of the combination of MEK1/2 inhibitors and EBV-specific T cells compared the individual treatment (Figure 10).

[0176] Further, to validate the impact of the combination on the
15 cell proliferation of the EBV-associated cancer cells, we challenged SNU719 and C666.1 cells with individual and dual combination using Xcellegence. We observed that the dual combination resulted in faster cell death of SNU719 and C666.1 cells compared to individual treatment of either MEK1/2 inhibitor (selumatinib) or HLA matched EBV-specific T cells (Figure 11A).
20 We also performed phenotypic characterization, using flow cytometry, of SNU719 and C666.1 cells after 16 hours of individual and dual treatment *in vitro*. We observed that the dual treatment resulted in significant loss of cell proliferation (indicated by Ki67^+ staining) and caused significant cell death as indicated Active Caspase 3 staining, compared to individual treatment
25 (Figure 11B-C).

[0177] Next, we wanted to determine the specificity of the combination and as such we challenged SNU719 and C666.1 cells with HLA-mismatched allogeneic T cells alongside MEK1/2 inhibitors (both selumetanib and trematinib), individually and in combination. We observed
30 that the HLA-mismatched allogeneic T cells individually did not have significant impact on the cell viability of the EBV-associated cancer cells (Figure 12A-B). Interestingly, we observed significant reduction in cell viability of the cancer cells in presence of the dual combination of MEK1/2 inhibitors and HLA-mismatch allogeneic T cells compared to DMSO treated
35 (control) cancer cells (Figure 12A-B). However, the reduced cell viability observed in the presence of dual combination demonstrated no significant

reduction in cell viability compared to treatment of MEK1/2 inhibitors alone (Figure 12A-B). This data highlights that the reduced cell viability observed in the presence of dual combination is induced due to inhibition of MAPK pathway alone and the addition of HLA-mismatched T cells did not enhance the efficacy of the combination. To further validate this concept, we compared the reduction in cell viability of the EBV-associated cancer cells (SNU719 and C666.1) caused by the respective HLA-matched and HLA-mismatched T cells alone and in combination with MEK1/2 inhibitors (both selumetinib and trametinib). We observed that alone, the HLA-matched T cells induced significant cell death compared HLA-mismatched T cells and this effect is significantly amplified in presence of either selumetinib or trametinib (Figure 12C).

[0178] In next set of experiments, we wanted to investigate the effect of the dual combination on the cancer cell intrinsic pathway and describe the rationale of the effective combination of MEK1/2 inhibition with T cell treatment. We observed that the presence of MEK1/2 inhibitor (selumetinib) resulted in significant reduction of pERK1/2 (Figure 13A) in the cancer cells, after 16 hours of treatment. As a result, we observed upregulation of MHC-Class I expression in presence of selumetinib alone and in combination with respective HLA-matched T cells (Figure 13B). To validate the mechanism via which MHC-Class I expression is upregulated in these cancer cells, we investigated the impact of MEK1/2 inhibition on pSTAT3 and MYC expression. We observed that presence of selumetinib resulted in upregulation of pSTAT3 expression (Figure 13C), which has been shown to be associated with driving MHC-class I expression [29, 35, 36]. In addition, we also observed that MEK1/2 inhibition resulted in downregulation of MYC expression (Figure 13D). Presence of MYC expression has been shown to downregulate MHC-class I expression in EBV-associated cancers and therefore its indirect inhibition probably assists MHC-class I in these cancers [37]. Thus, inhibition of MEK1/2 pathway results in upregulation of MHC-class I expression via upregulation of STAT3 pathway and downregulation of MYC which enables better therapeutic compatibility in presence of HLA-matched allogeneic T cells. Collectively, these results highlight the efficacy of the dual combination of MEK1/2 inhibition with EBV-specific T cells *in vitro*.

[0179] Similarly, we targeted MYC-dependent cancer intrinsic pathway using JQ1 inhibitor by first determining the IC₅₀ value of the inhibitor across nasopharyngeal and gastric cancer cell lines (with drug concentration ranging from 0.5 μ M-10 μ M). We observed that the JQ1 inhibitor demonstrated ~50% reduction in cell viability (IC₅₀) at a concentration of ~2.5 μ M among the EBV-associated cell lines compared to NPC43^(EBV-) cell line (Figure 14). To characterized the impact of JQ1 inhibition in combination with allogeneic EBV-specific T cells on EBV-associated cancer cells, we used IC₂₅ value JQ1 (2.5 μ M) alongside an effector to target ratio of 25:1 of the respective HLA matched allogeneic EBV-specific T cells *in vitro*. We observed that the cell viability of the respective gastric cancer cells (SNU719 and YCCLE1) and nasopharyngeal (C17 and C666.1) was significantly reduced in presence of the combination of JQ1 inhibitor and EBV-specific T cells compared the individual treatment (Figure 15A). Further, using Xcellegence, we observed that the dual combination resulted in faster cell death of SNU719 and C666.1 cells compared to individual treatment (Figure 15B). We also performed phenotypic characterization, using flow cytometry, of SNU719 and C666.1 cells after 16 hours of individual and dual treatment *in vitro*. We observed that the dual treatment resulted in significant loss of cell proliferation (indicated by Ki67⁺ staining) and caused significant cell death as indicated Active Caspase 3 staining, compared to individual treatment (Figure 15B-C).

[0180] Next, we wanted to determine the specificity of the combination and as such we challenged SNU719 and C666.1 cells with HLA-mismatch allogeneic T cells alongside JQ1 inhibitor individually and in combination. Consistent to our previous data with MEK1/2 inhibitors, we observed significant reduction in cell viability of the cancer cells in presence of the combination of JQ1 inhibitor and HLA-mismatch allogeneic T cells compared to DMSO treated (control) cancer cells (Figure 16A). However, the reduced cell viability observed in the presence of dual combination demonstrated no significant reduction in cell viability compared to treatment of JQ1 inhibitor alone (Figure 16A). We observed that alone, the HLA-matched T cells induced significant cell death compared HLA-mismatched T cells and this effects is significantly amplified in presence of JQ1 (Figure 16B). In next set of experiments, we wanted to investigate

rationale of the effective combination of JQ1 inhibition with T cell treatment. We observed that the presence of JQ1 inhibitor resulted in significant reduction of MYC expression (Figure 17A) in the cancer cells, after 16 hour of treatment. As a result, it caused downregulation of pERK1/2, pAKT and pSTAT3 expression (Figure 17B-C). In addition, we also observed that downregulation of MYC resulted in enhancing MHC-class I (Figure 18A) in these cancers, as discussed above [37]. Notably, we also observed downregulation of immune-regulatory molecules such as PD-L1 and CD47 expression (Figure 18B-C). Therefore, loss of MYC expression enhances the efficacy of cytotoxic T cells by enhancing MHC-Class I expression downregulating immune-evasion molecules making the combination to be highly effective. Collectively, these results highlight the efficacy of the dual combination of JQ1 inhibition with EBV-specific T cells *in vitro*.

[0181] In next set of experiments, we wanted to investigate the effect of the above described small molecules in combination of HLA matched allogeneic EBV-specific T cells *in vivo*. We used the combination of selumatinib and HLA-matched T cell product (TIG-001) to treat SNU719 derived xenograft tumour model in female NRG mice. Once the xenograft reached the size of $\sim 25 \text{ mm}^2$, we treated the mice with two infusion of TIG-001 (2×10^7 cells per infusion) individually and in combination with daily dosage selumatinib (12.5 mg/kg), administered orally for 14 days. We observed that the dual combination resulted in significant reduction in tumour progression of compared to individual treatment (Figure 19A). We sacrificed three mice from each group when the control reached the ethical size limit of 150 mm^2 and comparatively we observed the size of the tumours in the dual combination group to be significantly smaller compared to individual treatment (Figure 19B-C). Next, we phenotyped the infiltration of the human origin lymphocytes in these tumours using flow cytometry. We observed that the combination group demonstrated significantly more number of viable CD45+CD3+CD8+ cells compared to individually treated T cell group (Figure 19D). We also performed long term monitoring of these post therapy (the mice from each group were monitored for tumour progression up to the ethical size limit of 150 mm^2) and observed that the dual combination group demonstrated better survival rate compared to individual treatment group (Figure 19E).

[0182] The citation of any reference herein should not be construed as an admission that such reference is available as "Prior Art" to the instant application.

[0183] Throughout the specification the aim has been to describe the preferred embodiments of the invention without limiting the invention to any one embodiment or specific collection of features. Those of skill in the art will therefore appreciate that, in light of the instant disclosure, various modifications and changes can be made in the particular embodiments exemplified without departing from the scope of the present invention. All such modifications and changes are intended to be included within the scope of the appended claims.

REFERENCES

- [1] C.S. Azimi, Q. Tang, K.T. Roybal, J.A. Bluestone, NextGen cell-based immunotherapies in cancer and other immune disorders, *Curr Opin Immunol*, 59 (2019) 79-87.
- [2] M.E. Dudley, J.R. Wunderlich, T.E. Shelton, J. Even, S.A. Rosenberg, Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients, *J Immunother*, 26 (2003) 332-342.
- [3] S.K. Parida, T. Poiret, L. Zhenjiang, Q. Meng, J. Heyckendorf, C. Lange, A.S. Ambati, M.V. Rao, D. Valentini, G. Ferrara, E. Rangelova, E. Dodoo, A. Zumla, M. Maeurer, T-Cell Therapy: Options for Infectious Diseases, *Clin Infect Dis*, 61Suppl 3 (2015) S217-224.
- [4] M. Hale, T. Mesojednik, G.S. Romano Ibarra, J. Sahni, A. Bernard, K. Sommer, A.M. Scharenberg, D.J. Rawlings, T.A. Wagner, Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells, *Mol Ther*, 25 (2017) 570-579.
- [5] C. Smith, G. Okern, S. Rehan, L. Beagley, S.K. Lee, T. Aarvak, K.W. Schjetne, R. Khanna, Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement, *Clin Transl Immunology*, 4 (2015) e31.
- [6] O.M. Pello, A.J. Innes, A. Bradshaw, S.A. Finn, S. Uddin, E. Bray, E. Olavarria, J.F. Apperley, J. Pavlu, BKV-specific T cells in the treatment of severe

refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation, *Eur J Haematol*, 98 (2017) 632-634.

[7] C. Smith, R. Khanna, Adoptive cellular immunotherapy for virus-associated cancers: a new paradigm in personalized medicine, *Immunol Cell Biol*, 95
5 (2017) 364-371.

[8] R. Khanna, S.R. Burrows, M.G. Kurilla, C.A. Jacob, I.S. Misko, T.B. Sculley, E. Kieff, D.J. Moss, Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development, *J Exp Med*, 176 (1992) 169-176.

10 [9] R.J. Murray, M.G. Kurilla, J.M. Brooks, W.A. Thomas, M. Rowe, E. Kieff, A.B. Rickinson, Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies, *J Exp Med*, 176 (1992) 157-168.

15 [10] M.P. Thompson, R. Kurzrock, Epstein-Barr virus and cancer, *Clin Cancer Res*, 10 (2004) 803-821.

[11] C. Smith, J. Tsang, L. Beagley, D. Chua, V. Lee, V. Li, D.J. Moss, W. Coman, K.H. Chan, J. Nicholls, D. Kwong, R. Khanna, Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy, *Cancer Res*, 72
20 (2012) 1116-1125.

[12] C. Smith, L. Cooper, M. Burgess, M. Rist, N. Webb, E. Lambley, J. Tellam, P. Marlton, J.F. Seymour, M. Gandhi, R. Khanna, Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope, *J Immunol*, 177 (2006) 4897-
25 4906.

[13] M. Kalimutho, D. Sinha, J. Jeffery, K. Nones, S. Srihari, W.C. Fernando, P.H. Duijf, C. Vennin, P. Raninga, D. Nanayakkara, D. Mittal, J.M. Saunus, S.R. Lakhani, J.A. Lopez, K.J. Spring, P. Timpson, B. Gabrielli, N. Waddell, K.K. Khanna, CEP55 is a determinant of cell fate during perturbed mitosis in breast
30 cancer, *EMBO Mol Med*, (2018).

[14] S.M. Smith, M.B. Wunder, D.A. Norris, Y.G. Shellman, A simple protocol for using a LDH-based cytotoxicity assay to assess the effects of death and growth inhibition at the same time, *PLoS One*, 6 (2011) e26908.

- [15] M. Kalimutho, D. Sinha, J. Jeffery, K. Nones, S. Srihari, W.C. Fernando, P.H. Duijf, C. Vennin, P. Ranninga, D. Nanayakkara, D. Mittal, J.M. Saunus, S.R. Lakhani, J.A. Lopez, K.J. Spring, P. Timpson, B. Gabrielli, N. Waddell, K.K. Khanna, CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer, *EMBO Mol Med*, 10 (2018).
- [16] J. Leignadier, S. Favre, S.A. Luther, I.F. Luescher, CD8 engineered cytotoxic T cells reprogram melanoma tumor environment, *Oncoimmunology*, 5 (2016) e1086861.
- [17] K.G. Anderson, I.M. Stromnes, P.D. Greenberg, Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies, *Cancer Cell*, 31 (2017) 311-325.
- [18] J.A. Rodriguez, HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation, *Oncol Lett*, 14 (2017) 4415-4427.
- [19] K.G. Lucas, Q. Sun, R.L. Burton, A. Tilden, W.P. Vaughan, M. Carabasi, D. Salzman, A. Ship, A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants, *Hum Gene Ther*, 11 (2000) 1453-1463.
- [20] P. Comoli, S. Basso, M. Zecca, D. Pagliara, F. Baldanti, M.E. Bernardo, W. Barberi, A. Moretta, M. Labirio, M. Paulli, M. Furione, R. Maccario, F. Locatelli, Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation, *Am J Transplant*, 7 (2007) 1648-1655.
- [21] R. Khanna, S. Bell, M. Sherritt, A. Galbraith, S.R. Burrows, L. Rafter, B. Clarke, R. Slaughter, M.C. Falk, J. Douglas, T. Williams, D.J. Moss, Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease, *Proc.Natl.Acad.Sci.U.S A.*, 1999, pp. 10391-10396.
- [22] B. Savoldo, J.A. Goss, M.M. Hammer, L. Zhang, T. Lopez, A.P. Gee, Y.F. Lin, R.E. Quiros-Tejeira, P. Reinke, S. Schubert, S. Gottschalk, M.J. Finegold, M.K. Brenner, C.M. Rooney, H.E. Heslop, Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs), *Blood*, 108 (2006) 2942-2949.

- [23] M. Vanneman, G. Dranoff, Combining immunotherapy and targeted therapies in cancer treatment, *Nat Rev Cancer*, 12 (2012) 237-251.
- [24] C. Liu, W. Peng, C. Xu, Y. Lou, M. Zhang, J.A. Wargo, J.Q. Chen, H.S. Li, S.S. Watowich, Y. Yang, D. Tompers Frederick, Z.A. Cooper, R.M. Mbofung, M. Whittington, K.T. Flaherty, S.E. Woodman, M.A. Davies, L.G. Radvanyi, W.W. Overwijk, G. Lizee, P. Hwu, BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice, *Clin Cancer Res*, 19 (2013) 393-403.
- [25] P.J.R. Ebert, J. Cheung, Y. Yang, E. McNamara, R. Hong, M. Moskalenko, S.E. Gould, H. Maecker, B.A. Irving, J.M. Kim, M. Belvin, I. Mellman, MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade, *Immunity*, 44 (2016) 609-621.
- [26] A. Boni, A.P. Cogdill, P. Dang, D. Udayakumar, C.N. Njauw, C.M. Sloss, C.R. Ferrone, K.T. Flaherty, D.P. Lawrence, D.E. Fisher, H. Tsao, J.A. Wargo, Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function, *Cancer Res*, 70 (2010) 5213-5219.
- [27] D.T. Frederick, A. Piris, A.P. Cogdill, Z.A. Cooper, C. Lezcano, C.R. Ferrone, D. Mitra, A. Boni, L.P. Newton, C. Liu, W. Peng, R.J. Sullivan, D.P. Lawrence, F.S. Hodi, W.W. Overwijk, G. Lizee, G.F. Murphy, P. Hwu, K.T. Flaherty, D.E. Fisher, J.A. Wargo, BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma, *Clin Cancer Res*, 19 (2013) 1225-1231.
- [28] S. Hu-Lieskovan, S. Mok, B. Homet Moreno, J. Tsoi, L. Robert, L. Goedert, E.M. Pinheiro, R.C. Koya, T.G. Graeber, B. Comin-Anduix, A. Ribas, Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma, *Sci Transl Med*, 7 (2015) 279ra241.
- [29] S.H. Kang, B. Keam, Y.O. Ahn, H.R. Park, M. Kim, T.M. Kim, D.W. Kim, D.S. Heo, Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma, *Oncoimmunology*, 8 (2019) e1515057.
- [30] A.R. Karpf, D.A. Jones, Reactivating the expression of methylation silenced genes in human cancer, *Oncogene*, 21 (2002) 5496-5503.

- [31] H.J. Kim, S.C. Bae, Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs, *Am J Transl Res*, 3 (2011) 166-179.
- [32] Y. Kagoya, M. Nakatsugawa, Y. Yamashita, T. Ochi, T. Guo, M. Anczurowski, K. Saso, M.O. Butler, C.H. Arrowsmith, N. Hirano, BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models, *J Clin Invest*, 126 (2016) 3479-3494.
- [33] J.E. Delmore, G.C. Issa, M.E. Lemieux, P.B. Rahl, J. Shi, H.M. Jacobs, E. Kastritis, T. Gilpatrick, R.M. Paranal, J. Qi, M. Chesi, A.C. Schinzel, M.R. McKeown, T.P. Heffernan, C.R. Vakoc, P.L. Bergsagel, I.M. Ghobrial, P.G. Richardson, R.A. Young, W.C. Hahn, K.C. Anderson, A.L. Kung, J.E. Bradner, C.S. Mitsiades, BET bromodomain inhibition as a therapeutic strategy to target c-Myc, *Cell*, 146 (2011) 904-917.
- [34] S.C. Casey, L. Tong, Y. Li, R. Do, S. Walz, K.N. Fitzgerald, A.M. Gouw, V. Baylot, I. Gutgemann, M. Eilers, D.W. Felsher, MYC regulates the antitumor immune response through CD47 and PD-L1, *Science*, 352 (2016) 227-231.
- [35] M. Kalimutho, D. Sinha, D. Mittal, S. Srihari, D. Nanayakkara, S. Shafique, P. Raninga, P. Nag, K. Parsons, K.K. Khanna, Blockade of PDGFRbeta circumvents resistance to MEK-JAK inhibition via intratumoral CD8(+) T-cells infiltration in triple-negative breast cancer, *J Exp Clin Cancer Res*, 38 (2019) 85.
- [36] D.E. Johnson, R.A. O'Keefe, J.R. Grandis, Targeting the IL-6/JAK/STAT3 signalling axis in cancer, *Nat Rev Clin Oncol*, 15 (2018) 234-248.
- [37] C.S. Tudor, C.W. Dawson, J. Eckhardt, G. Niedobitek, A.C. Buttner, B. Seliger, A. Hartmann, M. Buettner, c-Myc and EBV-LMP1: two opposing regulators of the HLA class I antigen presentation machinery in epithelial cells, *Br J Cancer*, 106 (2012) 1980-1988.

CLAIMS

1. A method of treating or preventing an EBV-associated disease, disorder or condition in a subject, said method including the steps of:
 - 5 (a) administering to the subject a first population of allogeneic T cells that bind or recognize a first epitope of an EBV antigen; and
 - (b) administering to the subject a second population of allogeneic T cells that bind or recognize a second epitope of the EBV antigen or a further EBV antigen;
- 10 to thereby treat or prevent the EBV-associated disease, disorder or condition in the subject.
2. A pharmaceutical composition for treating or preventing an EBV-associated disease, disorder or condition in a subject, the composition
- 15 comprising:
 - a first population of allogeneic T cells that bind or recognize a first epitope of an EBV antigen;
 - a second population of allogeneic T cells that bind or recognize a second epitope of the EBV antigen or a further EBV antigen; and
- 20 optionally a pharmaceutically acceptable carrier, diluent and/or excipient.
3. The method of Claim 1 or the composition of Claim 2, wherein the first population of allogeneic T cells and cells of the EBV-associated disease, disorder
- 25 or condition both comprise or are restricted by a first human leukocyte antigen (HLA) allele that encodes a first MHC protein.
4. The method or composition of Claim 3, wherein the first MHC protein presents the first epitope of the EBV antigen on cells of the EBV-associated
- 30 disease, disorder or condition.
5. The method or composition of any one of Claims 1 to 4, wherein the second population of allogeneic T cells and cells of the EBV-associated disease, disorder or condition both comprise or are restricted by a second HLA allele that
- 35 encodes a second MHC protein.

6. The method or composition of Claim 5, wherein the second MHC protein presents the second epitope of the EBV antigen or the further EBV antigen on cells of the EBV-associated disease, disorder or condition.

5 7. The method of any one of Claims 1 and 3 to 6, wherein the second population of allogeneic T cells is administered prior to, simultaneously with and/or subsequent to administration of the first population of allogeneic T cells.

8. The method of any one of Claims 1 and 3 to 7, further including the
10 initial step of generating the first and/or second populations of allogeneic T cells *in vitro*.

9. The method of any one of Claims 1 and 3 to 8, including the further step of administering a therapeutic agent to the subject.

15

10. The method of Claim 9, wherein the therapeutic agent is selected from the group consisting of an immunotherapeutic agent, a MAPK pathway inhibitor, a BET inhibitor and any combination thereof.

20 11. A pharmaceutical combination, comprising the pharmaceutical composition of Claim 2, together with an immunotherapeutic agent, a MAPK pathway inhibitor, a BET inhibitor, or a combination thereof.

12. A method of treating or preventing an EBV-associated disease, disorder
25 or condition in a subject, said method including the steps of:

(a) administering to the subject a population of allogeneic T cells that bind or recognize an epitope of an EBV antigen; and

(b) administering to the subject a therapeutic agent, wherein the therapeutic agent is selected from the group consisting of an
30 immunotherapeutic agent, a MAPK pathway inhibitor, a BET inhibitor and any combination thereof;

to thereby treat or prevent the EBV-associated disease, disorder or condition in the subject.

35 13. A pharmaceutical composition for treating or preventing an EBV-associated disease, disorder or condition in a subject, the composition comprising:

a population of allogeneic T cells that bind or recognize an epitope of an EBV antigen;

a therapeutic agent, wherein the therapeutic agent is selected from the group consisting of an immunotherapeutic agent, a MAPK pathway inhibitor, a
5 BET inhibitor and any combination thereof; and

optionally a pharmaceutically acceptable carrier, diluent and/or excipient.

14. The method of Claim 12 or the composition of Claim 13, wherein the
10 population of allogeneic T cells and cells of the EBV-associated disease, disorder or condition both comprise or are restricted by a human leukocyte antigen (HLA) allele that encodes a MHC protein.

14. The method or composition of Claim 14, wherein the MHC protein
15 presents the epitope of the EBV antigen on cells of the EBV-associated disease, disorder or condition.

15. The method, combination, or composition of any one of Claims 10 to 15, wherein the immunotherapeutic agent is or comprises an immune checkpoint
20 inhibitor, such as a PD1 inhibitor (e.g., an anti-PD1 antibody), a PD-L1 inhibitor (e.g., an anti-PD-L1 antibody), a CTLA4 inhibitor (e.g., an anti-CTLA4 antibody), a LAG3 inhibitor (e.g., an anti-LAG3 antibody), a TIM3 inhibitor (e.g., an anti-TIM3 antibody), or a CD96 inhibitor (e.g., an anti-CD96 antibody).

25 16. The method or composition of Claim 15, wherein the immune checkpoint inhibitor is or comprises an anti-PD1 antibody.

17. The method or composition of Claim 16, wherein the anti-PD1 antibody
is selected from Pembrolizumab, Nivolumab, or Cemiplimab.

30

19. The method or composition of Claim 15, wherein the immune checkpoint inhibitor is or comprises an anti-PD-L1 antibody.

20. The method or composition of Claim 19, wherein the anti-PD1 antibody
35 is selected from Atezolizumab, Avelumab, or Durvalumab.

21. The method, combination, or composition of any one of Claims 10 to 16, wherein the MAPK pathway inhibitor is or comprises a MEK1/2 inhibitor.
22. The method or composition of claim 21, wherein the MEK1/2 inhibitor is
5 selected from selumetanib and/or trematinib.
23. The method, combination, or composition of any one of Claims 10 to 16, wherein the BET inhibitor is JQ1.
- 10 24. The method of any one of Claims 12 and 14 to 23, wherein the population of allogeneic T cells is administered prior to, simultaneously with and/or subsequent to administration of the therapeutic agent.
25. The method of any one of Claims 12 and 14 to 24, further including the
15 initial step of generating the population of allogeneic T cells *in vitro*.
26. The method or composition of any one of the preceding claims, wherein the EBV antigen and/or the further EBV antigen is selected from the group consisting of EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, LMP1, LMP2 and any
20 combination thereof.
27. The method or composition of Claim 26, wherein the EBV antigen and/or the further EBV antigen is or comprises EBNA1, LMP1 and/or LMP2.
- 25 28. The method or composition of any one of the preceding claims, wherein the EBV-associated disease, disorder or condition is or comprises an EBV-associated cancer.
23. The method or composition of Claim 22, wherein the EBV-associated
30 cancer is selected from the group consisting of nasopharyngeal carcinoma, NKT cell lymphoma, Hodgkin's Lymphoma, post-transplant lymphoproliferative disease, Burkitt's lymphoma, Diffuse large B-cell lymphoma, gastric cancer, and any combination thereof.
- 35 24. Use of a first population of allogeneic T cells that bind or recognize a first epitope of an EBV antigen in the manufacture of a medicament for the treatment or prevention of an EBV-associated disease, disorder or condition in

a subject; wherein the first population of allogeneic T cells is to be administered in combination with: (a) a second population of allogeneic T cells that bind or recognize a second epitope of the EBV antigen or a further EBV antigen; and/or (b) a therapeutic agent, wherein the therapeutic agent is selected from the group consisting of an immunotherapeutic agent, a MAPK pathway inhibitor, a BET inhibitor and any combination thereof.

25. A first population of allogeneic T cells that bind or recognize a first epitope of an EBV antigen for use in the treatment or prevention of an EBV-associated disease, disorder or condition in a subject; wherein the first population of allogeneic T cells is to be administered in combination with: (a) a second population of allogeneic T cells that bind or recognize a second epitope of the EBV antigen or a further EBV antigen; and/or (b) a therapeutic agent, wherein the therapeutic agent is selected from the group consisting of an immunotherapeutic agent, a MAPK pathway inhibitor, a BET inhibitor and any combination thereof.

26. A method of treating or preventing an EBV-associated cancer or tumour in a subject, said method including the steps of:

(a) administering to the subject a population of allogeneic T cells that bind or recognize an epitope of an EBV antigen; and

(b) administering to the subject a therapeutic agent, wherein the therapeutic agent is selected from the group consisting of an immunotherapeutic agent, a MAPK pathway inhibitor, a BET inhibitor and any combination thereof;

to thereby treat or prevent the EBV-associated disease, disorder or condition in the subject.

27. A pharmaceutical composition for treating or preventing an EBV-associated cancer or tumour in a subject, the composition comprising:

a population of allogeneic T cells that bind or recognize an epitope of an EBV antigen;

a therapeutic agent, wherein the therapeutic agent is selected from the group consisting of an immunotherapeutic agent, a MAPK pathway inhibitor, a BET inhibitor and any combination thereof; and

optionally a pharmaceutically acceptable carrier, diluent and/or excipient.

28. The method of Claim 26 or the composition of Claim 27, wherein the population of allogeneic T cells and cells of the EBV-associated disease, disorder or condition both comprise or are restricted by a human leukocyte antigen (HLA) allele that encodes a MHC protein.

29. The method or composition of Claim 28, wherein the MHC protein presents the epitope of the EBV antigen on cancer or tumour cells.

30. The method, combination, or composition of any one of Claims 26 to 29, wherein the immunotherapeutic agent is or comprises an immune checkpoint inhibitor, such as a PD1 inhibitor (e.g., an anti-PD1 antibody), a PD-L1 inhibitor (e.g., an anti-PD-L1 antibody), a CTLA4 inhibitor (e.g., an anti-CTLA4 antibody), a LAG3 inhibitor (e.g., an anti-LAG3 antibody), a TIM3 inhibitor (e.g., an anti-TIM3 antibody), or a CD96 inhibitor (e.g., an anti-CD96 antibody).

31. The method or composition of Claim 30, wherein the immune checkpoint inhibitor is or comprises an anti-PD1 antibody.

32. The method or composition of Claim 31, wherein the anti-PD1 antibody is selected from Pembrolizumab, Nivolumab, or Cemiplimab.

33. The method or composition of Claim 30, wherein the immune checkpoint inhibitor is or comprises an anti-PD-L1 antibody.

34. The method or composition of Claim 33, wherein the anti-PD1 antibody is selected from Atezolizumab, Avelumab, or Durvalumab.

35. The method, combination, or composition of any one of Claims 26 to 29, wherein the MAPK pathway inhibitor is or comprises a MEK1/2 inhibitor.

36. The method or composition of claim 35, wherein the MEK1/2 inhibitor is selected from selumetanib and/or trematinib.

37. The method or composition of any one of Claims 26 to 29, wherein the BET inhibitor is JQ1.

38. The method of any one of Claims 26 and 28 to 37, wherein the population of allogeneic T cells is administered prior to, simultaneously with and/or subsequent to administration of the therapeutic agent.

5 39. The method of any one of Claims 26 and 28 to 38, further including the initial step of generating the population of allogeneic T cells *in vitro*.

40. The method or composition of any one of claims 26 to 39, wherein the EBV antigen and/or the further EBV antigen is selected from the group
10 consisting of EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, LMP1, LMP2 and any combination thereof.

41. The method or composition of Claim 40, wherein the EBV antigen and/or the further EBV antigen is or comprises EBNA1, LMP1 and/or LMP2.

15

42. The method or composition of any one of Claims 26 to 41, wherein the cancer or tumour is selected from the group consisting of nasopharyngeal carcinoma, NKT cell lymphoma, Hodgkin's Lymphoma, post-transplant lymphoproliferative disease, Burkitt's lymphoma, Diffuse large B-cell
20 lymphoma, gastric cancer, and any combination thereof.




FIG. 1




FIG. 1 cont'd






FIG. 2





A



B




FIG. 4




FIG. 5




FIG. 5 cont'd




FIG. 6




FIG. 6 cont'd




FIG. 7




FIG. 7 cont'd




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU2020/051147

A. CLASSIFICATION OF SUBJECT MATTER

**C12N 5/0783 (2010.01) A61P 35/00 (2006.01) A61K 35/17 (2015.01) A61K 39/245 (2006.01) A61P 31/22 (2006.01)
A61K 39/395 (2006.01) A61K 39/12 (2006.01) C07K 16/28 (2006.01) A61K 31/551 (2006.01) A61K 31/4184 (2006.01)
A61K 31/519 (2006.01)**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPOQUE (PATENW =WPIAP, EPODOC and all full text databases in English) and Medline

STN - Embase, CAPLUS and Biosis databases.

Keywords - EBV, Epstein Barr virus, allogeneic, adoptive cell transfer immune checkpoint inhibitor and such like, The Council of the Queensland Institute of Medical Research, Khanna Rajiv, Sinha Debottam.

APPLICANT AND INVENTOR SEARCH: DATABASES: Patentscope, Auspat, Google, Google advanced patent search, Google scholar, Espacenet, PubMed.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	Documents are listed in the continuation of Box C	

☒ Further documents are listed in the continuation of Box C

☒ See patent family annex

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"D" document cited by the applicant in the international application	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

24 December 2020

Date of mailing of the international search report

24 December 2020

Name and mailing address of the ISA/AU

AUSTRALIAN PATENT OFFICE
PO BOX 200, WODEN ACT 2606, AUSTRALIA
Email address: pct@ipaustalia.gov.au

Authorised officer

Johanna Lowery
AUSTRALIAN PATENT OFFICE
(ISO 9001 Quality Certified Service)
Telephone No. +61262832968

INTERNATIONAL SEARCH REPORT		International application No.
C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		PCT/AU2020/051147
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2016/183153 A1 (MEMORIAL SLOAN KETTERING CANCER CENTER) 17 November 2016 [0017]-[0018], [0024]-[0029], claims	1-48
X	WO 2019/178170 A1 (MEMORIAL SLOAN KETTERING CANCER CENTER) 19 September 2019 Example-[00170]-[00178] especially, [0094]-[00101], [0089]-[0092]	1-48
X	WO 2019/136419 A2 (H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC.) 11 July 2019 p128-132	12-29, 31-48
X	DOUBROVINA, A. et al "Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation." Blood, Vol. 119, No. 11, page 2644-2656. 15 March 2012. Patient 8, page 2652, left hand column	1-48
X	EIZ-VESPER, B. et al "Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry." Frontiers in Immunology, Vol. 3, Article 410. Jan 2013.Published on 28 January 2013 Front. Immunol. doi: https://doi.org/10.3389/fimmu.2012.00410 Whole Document	1-48
X	ICHEVA, V. et al "Adoptive Transfer of Epstein-Barr Virus (EBV) Nuclear Antigen 1-specific T Cells As Treatment for EBV Reactivation and Lymphoproliferative Disorders After Allogeneic Stem-Cell Transplantation." Journal of Clinical Oncology, Vol. 31, No. 1, page 39-48. 1 January 2013. Whole Document	1-48
X	Lulla P, Heslop HE. "Checkpoint inhibition and cellular immunotherapy in lymphoma". Hematology, Am Soc Hematol Educ Program. 2016(1):390-396. 2 Dec 2016. Whole Document	1-48
Form PCT/ISA/210 (fifth sheet) (July 2019)		

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.

☐

Claims Nos.:

because they relate to subject matter not required to be searched by this Authority, namely:
the subject matter listed in Rule 39 on which, under Article 17(2)(a)(i), an international search is not required to be carried out, including

2.

☐

Claims Nos.:

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3.

☐

Claims Nos:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See Supplemental Box for Details

1.

☐

As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.

☒

As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3.

☐

As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.

☐

No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

- Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

☐

The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☐

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT	International application No. PCT/AU2020/051147
Supplemental Box	
Continuation of: Box III This International Application does not comply with the requirements of unity of invention because it does not relate to one invention or to a group of inventions so linked as to form a single general inventive concept. This Authority has found that there are different inventions based on the following features that separate the claims into distinct groups: • Claims 1-11, 26-30 (in full) and 16-23 and 31 (in part) are directed to methods and compositions comprising a first and second population of allogeneic T-cells specific for different EBV antigens in the treatment of EBV associated disorders. The feature of the means to using 2 populations of EBV specific allogeneic T-cells is specific to this group of claims. • Claims 12-15, 24-25 and 32-42 (in full) and 16-23 and 31 (in part) are directed to a combination of a population of EBV specific allogeneic T-cells and a further therapeutic agent, and the use of this combination in treating EBV associated disease. The feature of the means to a combination of allogeneic EBV specific T-cells and a further therapeutic agent is specific to this group of claims. PCT Rule 13.2, first sentence, states that unity of invention is only fulfilled when there is a technical relationship among the claimed inventions involving one or more of the same or corresponding special technical features. PCT Rule 13.2, second sentence, defines a special technical feature as a feature which makes a contribution over the prior art. When there is no special technical feature common to all the claimed inventions there is no unity of invention. In the above groups of claims, the identified features may have the potential to make a contribution over the prior art but are not common to all the claimed inventions and therefore cannot provide the required technical relationship. The only feature common to all of the claimed inventions and which provides a technical relationship among them is the use of allogeneic T-cells in treating EBV associated diseases However this feature does not make a contribution over the prior art because it is disclosed in: D1-D6 at least Therefore in the light of this document this common feature cannot be a special technical feature. Therefore there is no special technical feature common to all the claimed inventions and the requirements for unity of invention are consequently not satisfied <i>a posteriori</i>.	
Form PCT/ISA/210 (Supplemental Box) (July 2019)	

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/AU2020/051147	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
WO 2016/183153 A1	17 November 2016	WO 2016183153 A1	17 Nov 2016
		AR 104598 A1	02 Aug 2017
		AU 2016262484 A1	04 Jan 2018
		BR 112017024431 A2	24 Jul 2018
		CA 2984178 A1	17 Nov 2016
		CL 2017002846 A1	25 May 2018
		CN 107835690 A	23 Mar 2018
		EP 3294304 A1	21 Mar 2018
		EP 3294304 B1	29 Jan 2020
		HK 1244697 A1	17 Aug 2018
		JP 2018520095 A	26 Jul 2018
		KR 20180003575 A	09 Jan 2018
		MX 2017014257 A	20 Apr 2018
		PH 12017501993 A1	26 Mar 2018
		RU 2017143151 A	13 Jun 2019
		US 2018125891 A1	10 May 2018
		US 10568908 B2	25 Feb 2020
WO 2019/178170 A1	19 September 2019	WO 2019178170 A1	19 Sep 2019
WO 2019/136419 A2	11 July 2019	WO 2019136419 A2	11 Jul 2019
		AU 2019205422 A1	06 Aug 2020
		AU 2019207635 A1	06 Aug 2020
		BR 112020013910 A2	01 Dec 2020
		BR 112020013954 A2	01 Dec 2020
		CA 3087706 A1	11 Jul 2019
		CA 3088878 A1	18 Jul 2019
		CN 111867613 A	30 Oct 2020
		CN 112040957 A	04 Dec 2020
		EP 3737391 A2	18 Nov 2020
		EP 3737400 A1	18 Nov 2020
		US 2020345779 A1	05 Nov 2020
		WO 2019139888 A1	18 Jul 2019
		WO 2020102780 A1	22 May 2020
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.			
Form PCT/ISA/210 (Family Annex)(July 2019)			

INTERNATIONAL SEARCH REPORT Information on patent family members		International application No. PCT/AU2020/051147
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.		
Patent Document/s Cited in Search Report Publication NumberPublication Date		Patent Family Member/s Publication NumberPublication Date
End of Annex		
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001. Form PCT/ISA/210 (Family Annex)(July 2019)		